Aptinyx up 19% [Jul 1, 20]
Inovio Pharma down 27% [Jul 1, 20]
Annexon Biosciences (South San Francisco, CA; no SBIR, founded 2014) [raised] $100 million to move its two clinical-stage programs along and to continue advancing its preclinical pipeline. [Sarah de Crescenzo, xconomy.com, Jul 1, 20]
Amylyx Pharmaceuticals (Cambridge, MA; no SBIR) focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases, announced it has closed an oversubscribed $30 million Series B financing. [company press release, Jul 1, 20]
T2 Biosystems (Lexington, MA; no SBIR) has a rapid coronavirus diagnostic test: the T2SARS-CoV-2 Panel, which provides sample-to-answer results in less than two hours. It is being commercially distributed after validation and meeting requirements for an Emergency Use Authorization request to the FDA. [BostInno, Jun 30, 20]
The U.S. government plans to lend $700 million in coronavirus stimulus funds to trucking firm YRC Worldwide, in exchange for a 29.6% equity stake in the company, the Treasury Department said. [Wall Street Journal, Jul 1, 20] Trump might love the profit possibilities, since he berated "my generals" for not using military operations to collect money for the US Treasury.
Plug Power up 17% [Jun 29, 20]
Cleveland BioLabs down 42% [Jun 29, 20]
startup Cryosa (Roseville, MN; no SBIR) just wrapped up its Series A-2 financing round, raising $8.25 million. [to] develop therapies for obstructive sleep apnea, a condition that affects approximately 22 million people in the U.S. [Burl Gilyard, Twin Cities Business, June 25, 20]
Pandion Therapeutics (Watertown, MA; no SBIR) biotech developing engineered T cells for autoimmune diseases, filed to raise $75M in an IPO. [Rowan Walrath, BostInno, Jun 29. 20] totall funding $135M [crunchbase.com]
When loyalty matters most. FEMA warned states not to use COVID-19 testing supplies it bought under a $10.2 million contract after a ProPublica investigation last week showed the vendor was providing contaminated and unusable mini soda bottles. FEMA signed its first deal with Fillakit on May 7, just six days after the company was formed by an ex-telemarketer repeatedly accused of fraudulent practices over the past two decades. [Ryan Gabrielson and J. David McSwane, ProPublica, govexec.com, Jun 29, 20] Trump has systematically appointed loyalists as government agency heads, and removed inspectors general who found too many faults.
Akouos (Brookline, MA; $200K SBIR) up 29% [Jun 26, 20] a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss, announced the pricing of its [IPO] to raise $212.5 million [company press release, Jun 25, 20]
Translate Bio down 21% [Jun 26, 20]
Vielo Bio down 20% [Jun 26, 20]
Immumic down 15% [Jun 26, 20]
Artiva Biotherapeutics (San Diego, CA; no SBIR for the stealthy), an oncology company focused on developing and commercializing allogeneic natural killer (NK) cell therapies, announced today the launch of the company with the close of a $78 million Series A financing [to] develop off-the-shelf universal NK cells for use in combination with monoclonal antibody therapy and tumor targeting CAR-NK cell therapies. [companyp press release, Jun 26, 20]
Somatus (McLean, VA; no SBIR, founded 2016), a market leader in value-based kidney care, announced it has completed a Series C funding round of $64 million ... brings the Company’s total capital raised to over $105 million [company press release, Jun 23, 20]
self-driving cars have proven to be a technology that—unlike social media—doesn’t particularly favor disruptive startups. The immense capital costs and deadening development cycles are perfect for large companies who can wait out the lean times. [Bloomberg Technology, Jun 29, 20]
Too much tech. Michigan has introduced a bill designed to prevent employers from forcing their staff to accept microchip implants. [Charlie Osborne, ZDNet, June 29, 20]
Toward a dumber government. Trump signed an executive order to overhaul requirements federal agencies use when evaluating job candidates, seeking to downplay the importance of college degrees. The order requires agencies to increase the use of skill assessments and interviews with subject matter experts to determine an applicant's qualifications, rather than simply looking at educational achievements. [Eric Katz, govexec.com, Jun 27, 20] Congress may step in to control anti-intellectual Executive Order land. It's also possible that Trump doesn't know the realties of federal hiring and is only just showing off for his uneducated base.
President Trump signed an executive order that calls on the U.S. government to prosecute individuals who damage statues or monuments and to limit federal support to states and law-enforcement agencies that don’t protect them. [WSJ, Jun 26, 20] Such an order will run into the same wall his sanctuary city edict did: if the law establishing the handout to a jurisdicion did not include such a criterion, an Executive Order to do so is illegal. The showtime President cannot unilaterally change a law.
Voter supression alive and well. The Supreme Court rejected an emergency appeal that sought permission for voters in Texas to cast absentee ballots in this year’s elections if they feared coronavirus risks from voting in person. [WSJ, Jun 26, 20] Elections have consequences.
as my sweet southern Grandmother would say, "Bless their hearts, they're just special stupid. " [David Spencer, Bluffton, SC on NYT piece on MI gov Witmer, commenting on SC Repubs, NYT June 25, 20]
Trump’s Napalm Politics? They Began With Newt. Gingrich wrote the playbook for it all. The nastiness, the contempt for norms, the transformation of political opponents into enemies. [Jennifer Senior, New York Times, June 28, 20]
Nanoviricides up 20% [Jun 25, 20]
Replimune up 18% [Jun 25, 20]
Relay Therapeutics (Cambridge, MA; no SBIR) focused on solid tumors, filed for a $200M IPO. [Rowan Walrath, BostInno, Jun 25, 20] total funding $520M [crunchbase.com]
startup MarvelBiome [Woburn, MA; SBIR) raised $2.3M in equity, according to an SEC filing. [Rowan Walrath, BostInno, Jun 25, 20] with a vision of harnessing the power of microbes for treating various human diseases. We are focused on isolating, identifying, and characterizing microbial populations for novel therapeutic applications. [company website]
Gilead Sciences has agreed to pay $275 million for 49.9 percent of Pionyr Immunotherapeutics (South San Francisco, CA; no SBIR) plus the option to pay another $315 million and make the startup eligible for up to $1.15 billion more in milestone payments to acquire the remaining 50.1 percent. ... developing antibody drugs that take a new approach toward boosting the body’s anti-tumor efforts. [Sarah de Crescenzo, xconomy.com, Jun 23, 20]
Century Therapeutics announced its acquisition of Empirica Therapeutics to leverage its iPSC-derived allogeneic cell therapies against glioblastoma (GBM). [Century press release, Jun 23, 20]
Simcha Therapeutics (New Haven, CT; no SBIR) developing biologic drugs that modulate cytokine pathways, launched with $25m in Series A financing.... lead program involves a customized variant of interleukin-18 (IL-18), a cytokine with potent antitumor effects. [finsmes.com, Jun 25, 20]
Karyopharm Therapeutics announced that [FDA] has approved oral XPOVIO® (selinexor), the Company’s first-in-class, Selective Inhibitor of Nuclear Export (SINE) compound, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. [copany press release, Jun 22, 20]
Since 2005, the One North Carolina Small Business Program has made 423 SBIR/STTR matching awards worth nearly $26 million to more than 250 businesses throughout the state. [SSTI, Jun 24, 20]
With the wealthiest 10% owning 84% of all stocks, and with the bottom 75% owning none at all, a rising stock market does absolutely nothing for the wealth of two-thirds of Americans. [Nouriel Roubini, Project Syndicate, Jun 24, 20]
Loyalty first. The White House is intensifying an effort to hire Pentagon personnel with an undisputed allegiance to President Trump at a moment when his relationship with Defense Secretary has become strained, current and former officials said. [Missy Ryan, Paul Sonne, and Josh Dawsey, WashPost, June 25, 20] Probably will not affect SBIR unless shutdown threatens at new fiscal year start Oct 1. When funding is short, SBIR gets low priority.
Five Prime Thera up 18% [Jun 24, 20]
Shattuck Labs (Research Triangle Park, NC, and Austin, TX; no SBIR), a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC™) platform to develop a novel class of biologic medicines for the treatment of cancer and autoimmune disease, announced the closing of a $118 million Series B equity financing. [company press release, Jun 24, 20] total funding $175M [crunchbase.com]
Already, an estimated 100,000 small companies have shut permanently. [Caroline Mimbs Nyce, The Atlantic, Jun 23, 20]
Tom McTague [The Atlantic], who spoke to more than a dozen European officials and policy experts, writes: “As citizens of the world the United States created, we are accustomed to listening to those who loathe America, admire America, and fear America (sometimes all at the same time). But feeling pity for America? That one is new, even if the schadenfreude is painfully myopic.”
President Donald Trump came to office promising to build a wall around to America to keep foreigners out. He may leave it with foreigners building walls to keep Americans out. [Bloomberg, Jun 24, 20]
Flexible minions. a familiar pattern: President Donald Trump says something that doesn’t line up with the facts held by scientists and other experts at government agencies. Then, instead of pushing back, federal officials scramble to reconcile the fiction with their own public statements. [ProPublica, govexec.com, Jun 23, 20]
Translate Bio up 47% [Jun 23, 20] Sanofi Pasteur (France) and Translate Bio (Lexingon, MA; no SBIR), a clinical-stage messenger RNA (mRNA) therapeutics company, have agreed to expand their existing 2018 collaboration and license agreement to develop mRNA vaccines for infectious diseases. Translate Bio will receive a total upfront payment of $425 million, ... Translate Bio will also be eligible for potential future milestones and other payments up to $1.9 billion, including $450 million of milestones under the 2018 agreement. Of these potential milestones and other payments, approximately $360 million are anticipated over the next several years, inclusive of COVID-19 vaccine development milestones. [joint companies press release, Jun 23, 20]
Inovio Pharma up 41% [Jun 23, 20] announced it has received $71 million funding from the U.S. DOD] to support the large-scale manufacture of the company's proprietary CELLECTRA(R) 3PSP smart device and the procurement of CELLECTRA(R) 2000 devices, which are used to deliver INO-4800 directly into the skin. [company press release, Jun 23, 20]
Cyclerion Thera (Cambridge, MA; no SBIR) up 37% [Jun 23, 20]
AsclepiX Therapeutics (Baltimore, MD; $3.5M SBIR), biopharmaceutical company that uses computational biology to identify potent peptide regulators of vascular homeostasis for the treatment of retinal and other important diseases, announced that it has closed a $35 million Series A financing [which] will fund Phase 1/2a clinical trials of AXT107, the Company’s lead investigational drug, for the treatment of diabetic macular edema (DME), wet age-related macular degeneration (wet AMD) and macular edema secondary to retinal vein occlusion (RVO). [company press release, Jun 24, 20]
Engrail Therapeutics (San Diego, CA; no SBIR) announced the close of a $32 million Series A financing round [to] support the clinical development of its first pipeline asset, ENX-101, a sub-type selective GABA A modulator. [company press release, Jun 18, 20]
Glyscend Therapeutics (Baltimore, MD; no SBIR), developing novel treatments for type 2 diabetes (T2D) and related metabolic conditions, announced the closing of a $20.5 million Series A financing round [to] to support the development of the company’s novel oral polymer therapy for patients with T2D and other metabolic diseases. [company press release, Jun 11, 20]
Sure, Trump threatens China constantly, but he mainly follows through with trade wars that are the equivalent of punching himself in the face out of spite. [Bloomberg, Jun 23, 20]
Five Prime Therapeutics up 45% [Jun 22, 20]
Biomerica up 21% [Jun 22, 20]
Sarepta Therapeutics, the leader in precision genetic medicine for rare diseases, and Codiak BioSciences (Cambridge, MA; no SBIR), a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, announced a global research and option agreement to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing and RNA technologies for neuromuscular diseases. The engineered exosome approach offers the potential to effectively deliver genetic therapeutics without triggering the adaptive immune response. The two-year agreement includes up to five neuromuscular targets. Codiak is eligible to receive up to $72.5 million in upfront and near-term license payments plus research funding. Sarepta is granted an option to any of the candidates developed pursuant to the research alliance. [company press release, Jun 22, 20]
It’s not just that the USA has the highest number of coronavirus cases and deaths in the world. Republican political dysfunction has made a coherent campaign to fight the pandemic impossible. ... we’re seeing a combination of the blustering contempt for science that marks the conservative approach to climate change and the high tolerance for carnage that makes American gun culture unique. No matter how bad things get in red America, it’s hard to imagine where the political will to contain the virus will come from. [Michelle Goldberg, NY Times, Jun 22, 20
Feeling important and in control? The deeper challenge for us humans on Earth — Earth being only one of 40-some billion other Earthlike planets in our galaxy — is that our brains can’t figure out what to do with numbers. “The equation of luck and skill is, at its heart, probabilistic,” Konnikova writes. [Michael Paterniti reviewing THE BIGGEST BLUFF How I Learned to Pay Attention, Master Myself, and Win By Maria Konnikova, NY Times, Jun 23, 20]
Repare Therapeutics (Cambridge, MA and Canada; no SBIR) up 54% [Jun 19, 20], a leading precision oncology company enabled by our proprietary synthetic lethality approach to the discovery and development of novel therapeutics, announced the pricing of its upsized [IPO] to raise $220.0 million. [company press release, Jun 18, 20]
Celldex Thera up 29% [Jun 19, 20] announced the closing of its underwritten public offering to raise $150 million [company press release, Jun 18, 20]
Diamedica Thera up 22% [Jun 19, 20]
Anaptys Bio up 16% [Jun 19, 20]
Neurocrine Biosciences and Takeda Pharmaceutical announced a strategic collaboration to develop and commercialize compounds in Takeda’s early-to-mid-stage psychiatry pipeline. Specifically, Takeda granted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including three clinical stage assets for schizophrenia, treatment-resistant depression and anhedonia. ... Takeda will receive a total of $120 million USD in upfront cash. Additionally, Takeda will be entitled to development milestones of up to $495 million USD, commercial milestones of up to $1.4 billion USD and up to double-digit royalties on net sales. [joint press release, Jun 16, 20]
Assembly Biosciences (South San Francisco, CA; no SBIR), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, announced that the Company will regain worldwide rights to all microbiome gastrointestinal programs licensed under its collaboration agreement with AbbVie (formerly Allergan pre-acquisition). AbbVie has decided to terminate the research, development, collaboration and license agreement. This decision was not based on any efficacy, safety, or other data related to the collaboration programs. ... As of March 31, 2020, Assembly had cash, cash equivalents and investments totaling $249 million. [company press release, Jun 18, 20]
Epizyme (Cambridge, MA; no SBIR) a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the [FDA] has approved the supplemental New Drug Application (sNDA) for TAZVERIK™ (tazemetostat) for two distinct follicular lymphoma (FL) indications. [company press release, Jun 18, 20]
Ultragenyx Pharmaceutical (Novato, CA; no SBIR), a biopharmaceutical focused on the development and commercialization of novel products for rare and ultra-rare diseases, and Kyowa Kirin (Japan), a global specialty pharmaceutical company creating innovative medical solutions using the latest biotechnology, today announced that the [FDA] has approved Crysvita® (burosumab) for the treatment of fibroblast growth factor 23 (FGF23)-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adults and pediatric patients 2 years of age and older. Crysvita is a human antibody that blocks excess activity of FGF23, a hormone that causes phosphate urinary excretion and suppresses active vitamin D production by the kidney. [company press release, Jun 18, 20]
Alpine Immune Sciences (Seattle, WA; no SBIR), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, and AbbVie, a research-based global biopharmaceutical company, announced an exclusive worldwide option and license agreement for ALPN-101, a first-in-class dual CD28/ICOS costimulation antagonist. ... Alpine will receive an upfront payment of $60 million, and will also be eligible to receive up to an aggregate of $805 million for exercise of the option and success-based development, regulatory and commercial milestones. In addition, Alpine is eligible to receive tiered royalties on net sales of ALPN-101 [joint press release, Jun 18, 20]
Leidos's Dynetics (many SBIRs near the Huntsville AL flagpole) subsidiary has secured a potential 10-year, $356M contract to produce and maintain a suite of foreign radar simulators for use by the U.S. Air Force and the Department of Defense in enterprise-wide test efforts [Mary-Louise Hoffman, govconwire.com, Jun 22, 20]
Markets are the answer; what's the question? The problem with letting private investment alone drive innovation is that the money is skewed toward the most lucrative markets. The biggest practical uses of AI have been to optimize things like web search, ad targeting, speech and face recognition, and retail sales. ... the government has to take on a leading role in directing innovation to meet the public’s most pressing needs. That doesn’t sound like the government the US has now. [David Rotman, MIT Tech Review, July 2020] Free-market government's role is to invest for public benefit where there is no market, only a need.
Innovation. Matt Ridley tells us at the start of his new treatise on the subject, “is the most important fact about the modern world, but one of the least well understood.” Even as it functions as a powerful engine of prosperity — the accelerant of human progress — innovation remains the “great puzzle” that baffles technologists, economists and social scientists alike. [Jon Gertner reviewing Ridley's How Innovation Works: And Why It Flourishes in Freedom, WashPost, Jun 18, 20]
Sailors cheer, Navy brass jeer. In a reversal, the service’s top officer says further investigation revealed lapses in Capt. Brett Crozier’s judgment and actions aboard his COVID-stricken [aircraft carrier] ship. [Bradley Peniston, DefOne, Jun 22, 20]
Tribalism. [Nebraska] Republican Gov. Pete Ricketts has threatened to withhold funds from any county that requires people to wear a mask in public buildings. The Republican governor is forbidding counties to require residents to do something that will, at very minimal personal inconvenience, reduce the spread of covid-19 to their fellow Nebraskans.[Megan McArdle, WashPo, Jun 18,20] Like so many issues rooted in science and medicine, the pandemic is now fully entangled with ideological tribalism. [Lori Rozsa et al, WashPo, Jun 18, 20]
Guarded privacy, unguarded health. N.Y.C. Hired 3,000 Workers for Contact Tracing. It’s Not Going Well. workers have not had much success in getting information from people who test positive. [Sharon Otterman, NY Times, June 21, 2020]
Alpine Immune Sciences (Seattle, WA; no SBIR) up 135% [Jun 18, 20], a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, and AbbVie announced an exclusive worldwide option and license agreement for ALPN-101, a first-in-class dual CD28/ICOS costimulation antagonist. [joint press release, Jun 18, 20]
Anavex Life Sciences up 21% [Jun 18, 20]
CryoLife down 25% [Jun 18, 20]
IDEAYA Biosciences down 23% [Jun 18, 20]
Who's paying for MAGA? Critics of the administration’s actions on China say hawkish officials have overreached or adopted misguided measures — for example, pushing a trade war that has resulted in mainly American companies paying about $55 billion in tariffs and caused suffering among farmers, or starting tit-for-tat punishments against Chinese media organizations that have resulted in the expulsions of American reporters from China. [Edward Wong and Michael Crowley, NY Times, Jun 18, 20]
When you wish upon a star... Trump claims the coronavirus pandemic is ending. Data and the experts disagree. [Philip Bump, WashPo, Jun 18, 20] Do presidents have ex officio superior understanding?
IDEAYA Biosciences up 45% [Jun 17, 20]
Diamedica Thera up 19%[Jun 17, 20]
RAPT Thera up 16%[Jun 17, 20]
Chembio Diagnosticsdown 61% [Jun 17, 20] announced that [FDA] has revoked the Emergency Use Authorization granted to the company in April to sell its rapid test for the antibodies domestically. [James T. Madore and Ken Schachter, newsday.com, Jun 17, 20]
Immunic up 17%[Jun 17, 20]
Orca Bio (Menlo Park, CA; no SBIR) is coming out of stealth with a $192 million series D round that will propel a pipeline of “high precision” allogeneic cell therapies and the manufacturing technology behind those treatments. Founded in 2016, Orca Bio zeroed in on manufacturing to make bone marrow transplants safer and more effective. ... brings Orca’s total raised to nearly $300 million [Amirah Al Idrus, Fierce Biotech, Jun 17, 20]
Lassen Therapeutics (San Diego, CA; SBIR) announced it has emerged from stealth and secured $31 million in Series A financing to develop antibodies as potential treatments for fibrosis, rare diseases and oncology. [company press release, Jun 17, 20]
IDEAYA Biosciences up 43% [Jun 16, 20] IDEAYA Biosciences and GlaxoSmithKline plc (British)) announce a strategic partnership in Synthetic Lethality, an emerging field in Oncology. ... IDEAYA will lead the MAT2A program through early clinical development. IDEAYA is responsible for all costs of the MAT2A program prior to the GSK option exercise. Thereafter, IDEAYA is responsible for 20% of global development costs. IDEAYA will receive a 50% US profit share and ex-US royalties for the MAT2A and Werner Helicase programs and is responsible for 20% of global development costs for licensed products being developed with GSK. IDEAYA will receive global royalties for the Pol Theta program, and GSK will cover all research, development, and commercialization costs. [joint companies pres release, Jun 16, 20] Also, IDEAYA announced that it intends to offer and sell up to $60 million of shares of its common stock in an underwritten public offering [company press release, Jun 16, 20]
Annovis Bio up 26% [Jun 16, 20]
Vaxcyte up 15% [Jun 16, 20]
Federal Reserve Chairman Jerome Powell said the economy faces potentially significant long-term damage from higher unemployment and a wave of small business failures due to the coronavirus pandemic despite recent signs of an economic rebound. [WSJ, Jun 17, 20] Beware breezy economic claims by campaigning politicians because lying is an epidemic disease in politics.
Celldex Therapeutics up 37% [Jun 15, 20] announced the [$130M] pricing of its previously announced underwritten public offering. [company press release, Jun 15, 20]
Arcturus Therapeutics up 17% [Jun 15, 20]
Viela Bio (Gaithersburg, MD; no SBIR) announced that [FDA] has approved UPLIZNATM (inebilizumab-cdon) for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-AQP4 antibody positive as a twice-a-year maintenance regimen following initial doses. Approximately 80% of all patients with NMOSD test positive for anti-AQP4 antibodies. [company press release, Jun 11, 20]
BioIQ (Atlanta, GA; no SBIR) a healthcare engagement and clinical adherence technology platform company, announced today availability of the first home test for COVID-19 that combines COVID-19, Flu A / Flu B, and a 21 Test Respiratory Panel from a single saliva sample. Partnering with P23 Labs, one of the first laboratories to receive Emergency Use Authorization (EUA) from the [FDA] for home saliva collection for COVID-19, the availability of this home test signifies a major step forward in the next phase to combat COVID-19. [company press release, Jun 15, 20]
The truth is that government efforts to inform the public about the pandemic have been a colossal failure, which means that most people are hearing mixed and muffled messages about what to do. [Jonathan Bernstein, Bloomberg Opinion, Jun 15, 20] When messages on health depend on politics, disease gets an unfair advantage.
Vaxcyte (formerly Sutrovax, Foster City, CA; no SBIR, founded 2013) up 63% [Jun 12, 20] a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, announced the [IPO] pricing of $250.0 million [company press release, Jun 11, 20] prior funding $177M [crunchbase.com]
Avidity Biosciences (San Diego, CA; $200K SBIR) up 58% [Jun 12, 20] announced pricing of its [IPO] to raise $259M [company press release, Jun 11, 20]
Illumina received an emergency authorization from the FDA for its COVID-19 test designed to sequence the full genome of the novel coronavirus. [Conor Hale, Fierce Biotech, Jun 10, 20]
Lycia Therapeutics is launching out of Versant Ventures with $50 million to develop drugs targeting protein degradation in a new way. ... Enter Lycia’s lysosomal-targeting chimeras, LYTACs. Based on the work of Carolyn Bertozzi, Ph.D., a professor of chemistry and an investigator at the Howard Hughes Medical Institute at Stanford University, LYTACs are designed to “grab” proteins from cell membranes, or proteins that are in circulation, and “drag” them into the cell, where they are degraded by the lysosome. [Amirah Al Idrus, Fierce Biotech, Jun 9, 2020]
Cash is us. Facebook confirmed that it was also developing a venture capital fund to invest in promising start-ups. Other technology giants are engaging in similar behavior. Apple has bought at least four companies this year and released a new iPhone. Microsoft has purchased three cloud computing businesses. ... tech’s largest companies — still wildly profitable and flush with billions of dollars from years of corporate dominance — are deliberately laying the groundwork for a future where they will be bigger and more powerful than ever. [Mike Isaac, New York Times, Jun 13, 20] The monopoly building of the late 19C has re-emerged with a politically neutered federal government. If you want a government in thrall to large biz profit interests, vote for Trump re-election.
Public Education. In times of crisis, a government’s duty is to lead the public through a process of diagnosing the problem and identifying a shared plan for solving it. This is fundamentally an act of public education. ... When the pandemic hit, none of this happened. Trump, the person with the greatest power to educate the public and motivate the whole country behind a common purpose, declined to use that power. [Danielle Allen Foreign Affairs, J/A2020]
Celldex Therapeutics (Hampton NJ; $500K SBIR) up 82% [Jun 11, 20]
Myriad Gdnetics down 21% [Jun 11, 20]
Verve Therapeutics (Cambridge, MA; no SBIR, founded 2018) a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary heart disease, today announced it has raised $63 million in a Series A2 financing [to] use the genetic mutation and the gene editing technology CRISPR to turn off eight genes linked to high cholesterol. [company press release, Jun 11, 20]
Fulcrum Therapeutics (Cambridge, MA; no SBIR, founded 2016) announced the closing of a $68.5 million private placement pursuant to a securities purchase agreement [to] to fund research and development expenses, including the ongoing clinical development of losmapimod for facioscapulohumeral muscular dystrophy (FSHD), the initiation of clinical development of losmapimod for COVID-19 pending review of the Company’s recently filed investigational new drug application by [FDA], the advancement of its hemoglobinopathies program into clinical development and the advancement of both its discovery efforts and product engine capabilities. [company press release, Jun 11, 20] prior funding $140M [crunchbase.com]
The Senate Armed Services Committee voted 25-2 to approve annual authorization of Defense Department spending that exceeds levels requested by the administration in a number of areas, including emerging technology investments to keep pace with China, according to a summary the committee released today. [Mariam Baksh, nextgov.com, Jun 11, 20] Note: authorization s only permisssion, not demand, for appropriation - the money creating step. But these are welcoming days for deficit spending in trillions.
Only large companies with deep pockets will be able to ride out the storm, with the technology giants gaining most of all, as digital interactions become ever more important. A lingering epidemic combined with deep job losses, a prolonged recession, and an unprecedented debt burden will inevitably create tensions that turn into a political backlash—but against whom is as yet unclear. [Francis Fukuyama, Foreign Affars, J/A2020]
National Science Board (NSB) recently released its Vision 2030 report. It identifies the primary challenges facing the S&E enterprise in the United States, the essential elements of leadership, and a roadmap for implementing these recommendations and maintaining U.S. leadership in S&E for the next decade. [SSTI, Jun 10, 20]
China has embarked on a new trillion-dollar push to develop next-generation technologies such as artificial intelligence, data centers, mobile communications, in an effort to catapult the communist nation ahead of the U.S. in critical areas. [Liza Lin, Wall Street Journal, Jun 12, 20]
Trump announces rallies in states where new infections are surging. [The Hill, Jun 11, 20] Maybe he will thank the throng by shaking all their hands whle wearing a hazmat suit.
Arcadia Biosciences, a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients, announced it has entered into a binding term sheet with Industrial Seed Innovations (ISI), an Oregon-based industrial hemp breeding and seed company, to acquire its commercial and genetic assets, including its seed varieties, germplasm library and intellectual property. [company press release, Jun 10, 20]
Verve Therapeutics (Cambridge, MA; no SBIR, founded 2019), a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary heart disease, announced it has raised $63 million in a Series A2 financing [to] advance its lead program through IND-enabling studies and fuel follow-on pipeline programs. ... has raised a total of $123M [company press release, Jun 11, 20]
Two decades to cold nationalism. It is difficult now to remember how high American prestige was less than two decades ago, as recently as Sept. 10, 2001—that post-Cold War unipolar moment when the Yale University historian Paul Kennedy observed that the lone superpower had surpassed even ancient Rome in economic and military dominance—and how quickly that went off course. In what was possibly the worst strategic misdirection in U.S. history, Bush and his neoconservative abettors (who are all in hiding now, conceptually speaking) turned what should have been a globally unifying struggle against the international community’s remaining criminal holdouts, Islamist terrorists, into an exhausting imperialist game of invasion and whack-a-mole, exposing in the process America’s worst vulnerabilities on the ground and in the air. [Michael Hirsh, reviewing The Inevitability of Tragedy: Henry Kissinger and His World, by Barry Gewen, Foreign Policy, Jun 7, 20] You have to return to Lyndon Johnson's 1968 abdication for the start with Nixon-Kissinger of the long decline and recent nationalist abandonment of American hegemony.
Calyxt up 25% [Jun 9, 20]
Biomerica up 19% [Jun 9, 20]
ArcherDX (Boulder, CO; no SBIR) files IPO for up to $100 million [Jensen Werley, Denver Business Journal, Jun 9, 20] offers a robust platform for detecting variants associated with cancers and inherited diseases. [company website]
Histosonics (Plymouth,MN and Ann Arbor, MI; no SBIR), a medical technology company creating a non-invasive device that destroys cancerous tissue, has closed on $40 million in an oversubscribed Series C round [Maddy Kennedy, MinneInno, Jun 9, 20]
Akouos [Brookline, MA; $200K SBIR) is developing a gene therapy to address [hearing loss caused by genetic defects and it’s planning an IPO [for $100M] to finance the first tests of its approach in humans. [Frank Vinluan, xconomy.com, Jun 9, 20]
Dan Levangie [CEO of CereVasc (Boston, MA; no SBIR) CEO]'s medical device startup aims to treat hydrocephalus with a less invasive method that leverages newer technologies now in use for vascular and neurological procedures. As the company prepares to test its device in humans, it is announcing the close of $43.9 million in Series A financing [Frank Vinluan, xconomy.com, Jun 9, 20]
there is a war being waged on our institutions by the president. This war - foreign and domestic - has been a wild success. And these developments leave us weakened and at the mercy of ever-increasing centralized control in the hands of Donald Trump, a particular danger considering he lacks the knowledge and respect for these institutions to see their value and necessity. ... Trump has been the perfect vessel for [Steve] Bannon's vision to tear apart global infrastructure, take power and solidify control. [Jessica Tarlov, The Hill, Jun 9, 20]
the president who now fancies himself an expert on polling began the day by sharing a poll number that is by now pretty obviously made up. ... how his approval rating among Republicans is 96 percent, without ever citing a poll that includes that figure. [Philip Bump, WashPo, Jun 8, 20]
Intravacc (Netherlands), one of the leading translational research and development vaccine institutes with an extensive track record in developing viral and bacterial vaccines and Versatope (Lowell, MA; $1.1M SBIR) developing vaccines and therapeutics, announced that they have signed a research service agreement to further develop a universal vaccine against influenza based on Intravacc's innovative Outer Membrane Vesicles (OMV) technology. Both parties will collaborate to further advance the candidate vaccine through clinical development. signed a research service agreement to further develop a universal vaccine against influenza. Intravacc will provide its services to Versatope in bringing their universal influenza vaccine candidate, VT-105, towards their first clinical trials. [joint press release, Jun 8, 20]
Melinta Therapeutics has struck a deal to buy Tetraphase Pharmaceuticals (no SBIR). The deal, which follows a bidding war with AcelRx Pharmaceuticals (no SBIR), gives Melinta another approved product and potentially complementary R&D expertise to support its bid to bounce back from bankruptcy. [Nick Paul Taylor, Fierce Biotech, Jun 5, 20]
Chinook Therapeutics (Canada) is set to merge with fallen Big Pharma darling Aduro Biotech (Berkeley, CA; $700K SBIR) to create a kidney disease player with $180 million in cash. [Nick Paul Taylor, Fierce Biotech, Jun 3, 2020]
Yes, a chemical. No, there were not chemical irritants. Pepper spray is not a chemical irritant. It's not chemical[said USAG Barr]. [NPR, Jun 8, 20] Au contraire PepperBall’s website declares: “With multiple payload options and a proprietary chemical irritant that’s proven more effective from even greater distances, PepperBall® projectiles offer the protection and versatility for any situation.” (The company did not respond to a request for comment.) What’s that ingredient? It’s called pelargonic acid vanillylamide, or PAVA, a “synthetic'' form of capsaicin, the active ingredient in hot peppers. [Glenn Kessler, WashPo fact checker, Jun 8, 20]
Mr Podsnap was well to do, and stood very high in Mr Podsnap’s opinion. He never could make out why everybody was not quite satisfied, and he felt conscious that he set a brilliant social example in being particularly well satisfied with most things, and, above all other things, with himself. [Charles Dickens, Our Mutual Friend] But not being a natural born American, Podsnap was not eligible to compete with his mirror image, Mr Trump, in this century.
Annovis Bio up 18% [Jun 5, 20]
Liqudia Tech down 16% [Jun 5, 20]
We've been there.“There’s a lot of denial here, as there was in the 1930s,” said Eric Rauchway, a historian at the University of California, Davis, who has written extensively about the Great Depression. “At the beginning of the Depression, nobody wanted to admit that it was a crisis. The actions the government took were not adequate to the scope of the problem, yet they were very quick to say there had been a turnaround.” the evidence is everywhere if you look closely. [Neil Irwin, NY Times, Jun 6, 20] Politicians are positive when holding office, and negative when seeking office.
Kezar Life Sciences (South San Francisco, CA; no SBIR) up 73% [Jun 4, 20] announced updated results from the Phase 1b (Ph1b) portion of MISSION, which is evaluating the safety and tolerability of KZR-616 in patients with systemic lupus erythematosus (SLE) with and without nephritis. [company press release, Jun 3, 20]
Plug Power up 20% [Jun 4, 20]
Replimune up 16% [Jun 4, 20]
Novavax announced that the company has been awarded a contract by the [DoD] for the manufacturing of NVX‑CoV2373, Novavax’ COVID-19 vaccine candidate. NVX‑CoV2373 consists of a stable, prefusion protein antigen made using its proprietary the Defense Health Program, has agreed to fund up to $60 million to support Novavax in its production of several components of the vaccine that will be manufactured in the U.S. The agreement includes a 2020 delivery of 10 million doses of NVX‑CoV2373 for DoD that could be used in Phase 2/3 clinical trials or under an Emergency Use Authorization (EUA) if approved by the U.S. FDA. [company press release, Jun 3, 20] and the company inked a deal with Bothell, Washington-based AGC Biologics to manufacture an element of its Covid-19 vaccine candidate. And it tapped PolyPetide Group to also assist with production. [DCInno, Jun 4, 20]
NASA is calling all entrepreneurs through its newly-launched pilot Entrepreneurs Challenge to seek fresh ideas from new participants to bolster the agency’s science and space exploration goals with new tools and technologies, at lower costs. NASA’s Science Mission Directorate, based in Washington, D.C., is seeking novel ideas from technologists and entrepreneurs in areas including machine learning, artificial intelligence, autonomy, robotics and advanced sensors. White paper submissions are due Friday, June 26, with the challenge event to be held July 29. [DCInno, Jun 4, 20]
a survey from the Society for Human Resource Management (SHRM) found that 52 percent of small businesses expected to be out of business within six months. [SSTI, Jun 3, 20]
The Small Business Administration (SBA) recently rolled out a new website for the SBIR/STTR program which SBA administers. Reorganized and including new landing pages for entrepreneurs, support organizations, and federal agencies, the new page provides quicker and easier access to the right information. [SSTI, Jun 3, 20]
of the nine people of Chinese ethnicity who have been awarded Nobel Prizes in the sciences, eight were U.S. citizens or subsequently became U.S. citizens. [LEE HSIEN LOONG Singapore PM, Foreign Affairs, Jun 4, 20]
The 51-foot ladders. People are sawing through and climbing over Trump’s border wall. [Nick Miroff, WashPo, Jun 4, 20] As predicted by then AZ Gov Janet Napolitano, 50-foot wall? I'll show you a 51-foot ladder.
Translate Bio down 19% [Jun 3, 20]
PROMISS Diagnostics (Milwaukee, WI; no SBIR, founded 2017), developing an early-detection ovarian cancer test, has raised $400,000 in a seed round of funding, the company announced. PROMISS Diagnostics is a venture-stage biotech company that develops bio-analytical solutions to assist physicians in improving women’s health outcomes. [Milwaukee BizTimes, Apr 29, 20]
“No powerful political actor had set out to destroy the American political system itself — until, that is, Trump won the Republican nomination,” [Massa] Gessen writes. “He was probably the first major party nominee who ran not for president but for autocrat.” [Jennifer Szalai reviewing Surviving Autocracy, NY Times, Jun 3, 20]
Nanoscope Technologies (Bedford, TX; $2.6M prior SBIR, founded 2009) announced receiving a $2 million multi-year [NIH SBIR] to advance its therapeutic gene and delivery platform. “Through laser delivery, we have now overcome the limitation on size of the therapeutic genes that can be delivered”, said Subrata Batabyal, co-investigator of the grant. [Kevin Cummings, North Texas Inno, Jun 1, 20]
Dynavax Tech up 29% [Jun 1, 20]
Novavax up 15% [Jun 1, 20]
Arca biopharma down 27% [Jun 1, 20]
Codiak BioSciences ( Cambridge, MA; no SBIR) at the forefront of advancing engineered exosomes as a new class of biologic medicines, announced that it has entered into two strategic collaborations with the Ragon Institute of MGH, MIT and Harvard to investigate the potential of its exoVACC vaccine platform in (1) SARS-CoV-2, the virus that causes COVID-19, and in (2) human immunodeficiency virus (HIV). [company press release, Jun 1, 20] total funding $168M [crunchbase.com]
Personal Genome Diagnostics (Baltimore, MD; $1M SBIR) looks to raise $3.5M following FDA clearance for cancer diagnostics tech [Morgan Eichensehr, Baltimore Business Journal, May 27, 20]
No happy early morning in America. The U.S. economy could take the better part of a decade to fully recover from the coronavirus pandemic and related shutdowns. [Congressional Budget Office, Jun 1, 20]
Trump doing his thing. The belief in Beijing, Moscow and Berlin is that the U.S. can no longer lead the globe. ... For its part, the Chinese leadership seems to believe that it is impossible to conciliate Mr. Trump, but that there is also little to fear from him. ... They likely believe that the triple threat of the pandemic, economic crash and civil unrest in the U.S. will promote an American withdrawal from global issues no matter who wins in November. [Walter Russell Mead, Wall Street Journal, Jun 2, 20] Trump's America First now means America no longer first as walls, tariffs, and withdrawals do their work of estranging America.
Dynavax Tech up 26% [May 29, 20]
Minerva Neurosciences down 72% [May 29, 20] announced that the Phase 3 trial of roluperidone to treat negative symptoms in schizophrenia did not meet its primary (reduction in PANSS Marder Negative Symptoms Factor Score or NSFS) and key secondary (improvement in the Personal and Social Performance Scale Total Score or PSP) endpoints. [company press release, May 29, 20]
Macrogenics down 16% [May 29, 20]
VentureOhio announced that it plans to cease operations. The organization worked to attract venture capital for early-stage companies to Ohio. VentureOhio directors decided to wind down after losing its leader earlier this year and because the pandemic put its biggest event of the year, an awards dinner that usually attracts around 600 people, in jeopardy. Leaders say that their advocacy work will continue through other programs throughout the state,
Q. I don’t remember being taught much of anything about [the 1918 Spnish flu] in school. Why are we not more familiar with how devastating it was? A. Well, until a couple of decades ago, historians wrote only about what people did to people. It was very unusual for historians to write about what nature did to people. [Joe Heim interviewing John M. Barry, the author of The Great Influenza: The Story of the Deadliest Pandemic in History, WashPo, May 30, 20] If people and their polticians ignore or make up history, we will repeat epidemics about every decade. And with little appreciation of history and mathematics, the country will be putty in the hands of unscrupulous politicians.
Science doubted. A housing crisis is imminent. Many parts of the country are reopening prematurely. Protesters have stormed state capitals, demanding that businesses reopen. The country is starkly dividing between those who believe in science and those who don’t. [Roxane Gay, NY Times, May 30, 20] Politics creates a lot of experts with expertise that extends only to getting elected.
ARCA biopharma (Westminster, CO; no SIR) up 386% [May 28, 20] announced a new development program to evaluate AB201 (rNAPc2), a potent, selective inhibitor of tissue factor (TF), as a potential treatment for COVID-19 associated coagulopathy (CAC) and the related inflammatory response. CAC is one of the most serious adverse effects seen in COVID-19 patients. AB201 has previously undergone clinical testing through Phase 2 in more than 700 patients for other indications, generating substantial safety data, which the Company believes may enable more rapid development. [company press release, May 28, 30]
Phasebio Pharma up 36% [May 28, 20] receives clearance of IND application from U.S. FDA under Coronavirus Treatment Acceleration Program (CTAP) "VANGARD" trial will assess the efficacy and safety of PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute respiratory distress syndrome Based on FDA feedback, PhaseBio believes that positive, clearly interpretable and clinically meaningful trial results may enable PhaseBio to submit a Biologics License Application [company press release, May 27, 30]
Five Prime Therapeutics down 16% [May 28, 20]
IDEAYA Biosciences up 23% [May 28, 20]
Novavax developing next-generation vaccines for serious infectious diseases, announced the acquisition of Praha Vaccines 9(Czech Republic) [for $167M] cash .... includes a biologics manufacturing facility and associated assets in Czech Republic. The facility is expected to provide an annual capacity of over 1 billion doses of antigen starting in 2021 for NVX‑CoV2373, Novavax’ COVID-19 vaccine candidate [compamy press release, May 27, 20]
Six months after banking a $100 million venture round, Avidity Biosciences (La Jolla, CA; $200K SBIR) is heading to the public market. The company filed to raise up to $100 million in its IPO, which will push its lead muscle disorder program through IND-enabling studies and into the clinic in 2021. [Amirah Al Idrus, Fierce Biotech, May 26, 20]
Wake-up coming. Subsidies will soon end. Americans will then feel the economic pain—and revolt. Historically, American elections after a crisis have been decided on the question of who can more competently lead the country to better days. Yet unlike previous challenges, the true nature of America’s economic crisis hasn’t set in on the American people. When it does, the familiar political fault lines fused with millions unemployed could make 2020 the most explosive ideological election in modern history. [Josh Holmes, Wall Street Journal, May 29, 20]
Mersana Thera (Cambridge, MA; no SBIR) up 69% [May 27, 20] a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today reported interim safety, tolerability and efficacy data from the ongoing expansion portion of the Phase 1 study evaluating XMT-1536, its first-in-class ADC candidate targeting NaPi2b, in patients with ovarian cancer and non-small cell lung (NSCLC) adenocarcinoma. [company press release, May 27, 20]
Arcturus Thera down 29% [May 27, 20]
Q32 Bio (Cambridge, MA; no SBIR) developing biologics to restore healthy immune regulation, announced the company's pipeline and plans to enter the clinic this year with its lead candidate. Enabled by a $46M Series A financing [is] advancing a portfolio of biologics targeting the body's innate and adaptive immune systems. The company has a robust product pipeline including a monoclonal antibody antagonist of the interleukin-7 receptor (IL-7R), and a complement therapeutics platform that has generated fusion proteins that downregulate complement activity specifically in disease-affected tissues. [company press release, May 27, 20]
RE2 Robotics (Pittsburgh, PA; no SBIR), a developer of human-like robotic manipulation systems, has received $2.5 million in funding from the Office of Naval Research to continue the development and commercialization of its technology under the Dexterous Maritime Manipulation System (DM2S) program. [David Edwards, Robotics & Automation, May 27 20]
Virna Therapeutics (Boston, MA: no SBIR) announces that they are partnering with University of Toronto to in-license neutralizing antibodies, to treat COVID-19. The discovery was made in the laboratory of Sachdev Sidhu, PhD., a professor of Molecular Genetics at the University of Toronto ... Virna Therapeutics has a three-pronged strategy to target the COVID-19 virus: (1) neutralizing antibodies that will prevent the virus from entering host cells, (2) CRISPR/Cas13d-based and LNA-based technologies for the treatment and prevention of RNA virus infection and (3) novel protease inhibitors that will prevent replication and release from host cells. [company press release, May 27, 20]
Investors have just pumped $27.5 million into Nanotech Energy (Los Angeles, CA; no SBIR) Because the company claims its graphene based lithium batteries can charge 18 times faster than conventional lithium-ion batteries. [Steve Hanley, Cleantechnica, May 25, 20]
A group of bipartisan lawmakers introduced legislation to boost research into emerging technology including artificial intelligence and quantum computing. The Endless Frontiers Act would create a Directorate of Technology at the National Science Foundation (NSF), and would rename the NSF the National Science and Technology Foundation. The new directorate would be given $100 billion over five years to invest in American science and technology research, with specific research areas including cybersecurity, robotics, AI, quantum computing, national disaster prevention and biotechnologies. In addition, the Department of Commerce would be given $10 billion over five years to establish “regional technology hubs” across the nation. [Maggie Miller, The Hill, May 27, 20]
Moderna down 16% [May 26, 20]
Purinomia Biotech (Woburn, MA; no SBIR), which focuses on biologicals and small molecule development to target key ectonucleotidases for treatment of cancer, autoimmunity, inflammatory disease and metabolic syndrome, raised $2.8M in equity in a $3.8M funding round, according to an SEC filing. [Srividya Kalyanaraman, BostInno, May 26, 20]
GelSight (Waltham, MA; $200K SBIR) announced that it has been awarded a $728,000 [NSF SBIR] grant to develop a compact sensor toolkit that will provide human-like tactile sensing capabilities for robotics.[company press release, May 26, 20] prior funding $10M [crunchbase.com]
Savi Technology (Alexandria, VA; $2.4M SBIR) is working with the Department of Defense to get its logistics tech to the Army National Guard, a 221-unit order amounting to $3.2M in business. It’s one of two multimillion-dollar orders from the DoD, to help get first responders logistics equipment — Savi’s Portable Deployment Kit, as it’s called — amid the coronavirus crisis. The other? The Army Reserve’s $5.1M order for 354 units [DCInno, May 26, 20]
Xeris Pharmaceuticals (Chicago, IL; no SBIR) up 28% [May 22, 20], a specialty pharmaceutical company leveraging its novel formulation platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced positive findings from the outpatient stage of a Phase 2 proof-of-concept study of its developmental ready-to-use (RTU) glucagon in patients who experience postprandial hypoglycemic episodes following bariatric surgery. [company press release, May 22, 20]
Zynerba Pharma up 18% [May 22, 20]
AMAG Pharmaceuticals has completed the sale of its rights to vaginal pain relief drug Intrarosa to Millicent Pharma Limited. The sale is worth up to $125M. [company press release, May 21, 20]
Biotech Day One Pharmaceuticals (Menlo Park, CA; no SBIR) debuts with $60M to change cancer care—starting with children. The drug has been tested in more than 250 patients, adults and children, and it’s in an investigator-sponsored trial testing it in children with relapsed gliomas. [Amirah Al Idrus, Fierce Biotech, May 21, 20]
SQZ Biotech (Watertown, MA; $1.7M SBIR) a clinical stage cell therapy c ompany developing innovative treatments for multiple therapeutic areas, announced the completion of a $65 million Series D preferred stock financing. [company press release, May 18, 20] total funding $166M [crunchbase.com]
Atea Pharmaceuticals (Boston, MA; no SBIR), a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections, today announced a $215 million Series D financing [company press release, May 20, 20]
Inflammatory disease biotech Applied Molecular Transport [South San Francisco, CA; no SBIR) aims for $100M IPO to bring its lead program, an oral IL-10 agonist, into phase 2 studies. [Amirah Al Idrus, Fierce Biotech, May 19, 20] total funding $73M [crunchbase.com]
A staggeringly large proportion of people in the so-called "free world" have the emotional maturity of toddlers; they genuinely think their immediate desire is an existential need. Those countries who have done well in this crisis are those with unified, socially-cohesive populations who recognise the simple truth: "What is good for all of us, is probably good for me too." [commenter, NYTimes, May 24, 20]
One of Donald Trump’s special talents is to hold every conceivable position on a given subject at the same time. [The Economist, Apr 18, 20]
Nanoviricides down 16% [May 21, 20]
Mammoth Biosciences (South San Francisco, CA; no SBIR), is leveraging its CRISPR-based DETECTR platform with GSK Consumer Healthcare’s global reach and commercialization expertise to develop an accurate, easy-to-use, fully disposable, rapid and handheld test that consumers and health care providers in clinics can use to detect active SARS-CoV-2, the novel coronavirus that causes COVID-19. [Christine Hall, crunchbase news, May 20, 2020] What happens to test results is unclear.
Aperiomics (Sterling, VA). has teamed up with biotech Antibody Biopharm (Gaithersburg, MD) to offer a rapid antibody test for Covid-19. The Loudoun County diagnostics startup has used its existing testing platform — the same tech involved in its own testing kits — in its Northern Virginia lab to validate and, now, begin offering the test to other laboratories that meet Clinical Laboratory Improvement Amendments, or CLIA, requirements. But the partners still need a nod from the FDA to administer the test as a point-of-care diagnostic given by doctors and other health care providers, which Aperiomics said it expects within two months. [DCInno, May 21, 20]
[DOD] has shelved some of its most ambitious laser plans in order to focus on getting fiber lasers up to a power level where they will actually be useful. especially for lasers on planes to shoot down ICBMs, says Mike Griffin, top DOD science leader and former 1990s overseer of Stars Wars tech group that contained my SBIR program. [Patrick Tucker, DefOne, May 21, 20]
The annual DOD budget battle is on, with a request for $700+B, to do what? We are pulling out of our international role of the hegemonic world organizer and defender. East Asia will have to defend itself from the expanding regional hegemon. World shipping powers will protect the sea lanes. The US will defend itself from Mexican border invasions with a magic wall. And taxes can be cut for the abused wealthy. We used to call that a peace dividend, especially in 1992 when the Bush 41 establishment, and then Clinton, discovered the use of SBIR for dual-use technology.
Act in haste. Hundreds of millions of dollars in unemployment funds were lost to fraud even as jobless claims soar. [New York Times, May 22, 20] A law passed in haste, to be admininstered by an Executive Branch stuffed by loyalists nto the Grupenfuhrer, with control devolved to private enterprise sound like something right of the 19th century. Act in haste, repent at leisure.
For Spy Agencies, Briefing Trump Is a Test of Holding His Attention [NY Times, May 22, 20] When your audience is only thinking of what he will say next, he may miss the message about a possible pandemic. You, of course, will be blamed when it happens.
Liquidia Tech up 18% [May 20, 20]
Vir Biotech up 17% [May 20, 20]
Immunogen up 16% [May 20, 20]
Novavax filed a prospectus to sell up to $250 million of shares of common stock as it prepares to scale up production of its coronavirus vaccine candidate. [yahoofinance.com, May 20, 20]
HotSpot Therapeutics (Boston, MA; no SBIR) a biotechnology company pioneering the discovery and development of first-in-class allosteric therapies targeting nature’s regulatory sites, announced the completion of a $65 million Series B financing. .... to realize our vision of designing and developing first-in-class allosteric medicines,” said Jonathan Montagu, CEO and co-founder [company press release, May 21, 20]
Vividion Therapeutics (San Diego, CA; no SBIR), discovering and developing highly selective small molecule medicines that drug traditionally inaccessible targets, announced it has entered into an exclusive worldwide option and license agreement with Roche to leverage its proteomics screening platform and proprietary small molecule library to target novel E3 ligases, as well as a range ofoncology and immunology therapeutic targets. Roche has the exclusive right to license resulting compounds at different stages of development. will receive $135 million in a cash upfront payment from Roche and is eligible to receive several billion dollars in payments based on the achievement of preclinical, development and commercial milestones, as well as royalties on sales of commercialized products resulting from the collaboration. [company press release, May 21, 20]
Exceptional nation. The United States’ military might and economic prowess remain unrivaled. America’s cultural influence and soft power remain enormous, even with the most inward-looking president in over a century sitting in the White House. It should also surprise no one that a country born in the Age of Enlightenment would thrive so mightily in science, medicine and technology. [Joe Scarborough, WashPo, May 20, 20] Trump shows no grasp of the exceptional nature of US history that brought it to a wholesome influence on the whole world. He lives in a 19th century mercantile world of whoever has the most gold wins.
Dynavax Tech (Berkeley, CA; $6.5M SBIR) up 34% [May 19, 20] in anticipation of the company's COVID-19 vaccine program update, which is scheduled for later today. One of the main reasons for all the excitement is that Dynavax has already announced that one or more of its collaboration partners should initiate an early stage COVID-19 vaccine trial by July. [Motley Fool, May 19, 20]
Bellerophon Pharma down 20% [May 19, 20] announced the pricing of offerings its common stock at a public offering [company press release, May 19, 20]
Sorrento Thera down 17% [May 19, 20]
immuno-oncology startup Scorpion Therapeutics (Boston, MA; no SBIR) raised $24.7M in equity, according to an SEC filing. [Rowan Walrath, BostInno, May 19, 20]
NBD Nanotechnologies (Lexington, MA; $1.5M SBIR) which develops advanced liquid repellant surface coatings and additives, raised $1M in debt in a $2.3M funding round, according to an SEC filing. [Srividya Kalyanaraman, BostInno, May 19, 20] prior funding $15M [crunchbase.com]
food supplements company ChromaDex (Westwood, CA; $800K SBIR) announced the expansion of its partnership with A.S. Watson Group into Europe and the launch of its main product, Tru Niagen, in more than 200 Superdrug stores across the United Kingdom. [LA Business Journal, May 18, 20]
In a book published more than a decade ago, I argued that the internet might lead to a choose-your-own-facts world in which different segments of society believe in different versions of reality. The Trump era, and now the coronavirus, has confirmed this grim prediction. [Farhad Manjoo, NY Times, May 20, 20]
Anything but science. ask what evidence Trump had that the [hydroxecholorquine] drug was at all efficacious in addressing the virus and disease it causes, covid-19. Simple, Trump replied: Lots of people called him and said it worked. [Philip Bump, WashPo, May 19, 20] A man who hears only what he wants to believe. All grievance politics, all the time.
Moderna up 20% [May 18, 20] reported “positive” data on its potential coronavirus vaccine from an early clinical trial, raising hopes about the effort. [The Hill, May 18, 20] announced itt will sell $1.25 billion worth of stock to fund manufacturing and distribution of its vaccine candidate, referred to as mRNA-1273, [Yahoo finance, May 18, 20] The company said early data from a Phase 1 clinical trial showed that people given the potential vaccine generated an immune response similar to that in people who had recovered from the disease.
Amplyx Pharmaceuticals (San Diego, CA; $11M SBIR) a biotech company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, announced it has closed a $53 million Series C extension, which brings the Series C round to over $90 million [to] advance the clinical development of the company’s product candidates, fosmanogepix and MAU868. [company press release May 19, 20]
Rallybio (New Haven, CT; no SBIR) committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the completion of a $145 million Series B financing [to] advance Rallybio’s current portfolio of product candidates targeting devastating rare diseases, including its lead program, RLYB211. RLYB211 is in development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns. [company press release May 19, 20]
Vir Biotech up 32% [May 18, 20] announced the publication of research findings from the company's efforts to develop therapeutics for COVID-19 in the May 18, 2020 issue of the journal Nature. The paper, entitled "Cross-neutralization of SARS-CoV and SARS-CoV2 by a human monoclonal antibody" (Pinto, et al., Nature), details the identification and characterization of S309, an antibody isolated from a patient who recovered from severe acute respiratory syndrome (SARS) in 2003, which has been shown to prevent SARS-CoV-2 live virus infection of cells. [company press release, May 18, 20]
Novavax up 30% [May 18, 20]
Translate Bio up 23% [May 18, 20]
Zynerba Pharma up 22% [May 18, 20]
FDA approved Deciphera Pharmaceuticals (Walham, MA; no SBIR) drug ripretinib (Qinlock), a new treatment intended for patients with a gastrointestinal stromal tumor (GIST) who have failed at least three previous treatments. [Sarah de Crescenzo, xconomy.com, May 15, 20]
OnKure Therapeutics (Boulder, CO; no SBIR), developing small molecule drugs for cancer treatment, raised $3.2 million in equity funding as part of a $5.2 million round, according to a Form D filing. The company spun out of research performed in a CU Boulder biochemistry lab and enrolled its first cancer patient in clinical trials last year. [Colorado Inno]
America Alone, again. A time must come when the United States as a powerful world state and a great creditor nation, hence vitally interested in world trade and world prosperity, will realize that a policy of self-sufficiency is not only impossible, but that a policy which presupposes it to be possible is stultifying and impoverishing. [Edwin Gay, Foreign Affairs, Jul 1932]
To govern, at least at the level of the presidency, is to make hard choices among competing options with incomplete information. Easier problems are resolved before they ever reach the Oval Office. Neither scientific data nor public sentiments can properly [alone] answer the questions that face elected officials. Both are important and must be integrated into the judgments that political leaders make. [Wall Sreeet Journal, May 16, 20] To govern is to choose, and therby make enemies. Elections choose whch leader will have to make those choices. Think carefully for whom to vote. Trump apparently denies the Adam Smith's economic principle of comparative advantage.
We got ours. With jobless numbers rising, Republicans’ refusal to negotiate on another round of pandemic relief is proving difficult to sustain. [Carl Hulse, NY Times, May 15, 20]
Sorrento Therapeutics (San Diego, $4.8M SBIR thru 2014, 300 employees) up 158% [May 15, 20] announced that its anti-SARS-CoV-2 antibody, STI-1499, demonstrated 100% inhibition of SARS-CoV-2 virus infection in an in vitro virus infection experiment at a very low antibody concentration. [company press release, May 15, 20] But was effective in a laboratory setting, which precedes any clinical trials. There is not yet any evidence that the treatment candidate is safe or effective in human beings. [Charley Grant, WSJ, May 15, 20]
Cassava Sciences (Austin, TX; no SBIR down 74% [May 15, 20] reported top-line results from a Phase 2b study of PTI-125, its lead investigational drug, in patients with Alzheimer's disease. This study did not meet its primary endpoint. [company press release, May 15, 20]
Nanovircides down 17% [May 15, 20]
Immunology startup Immunai (NYC, NY) came out of stealth mode with $20 million in a seed funding round [to] build the world's largest proprietary clinical immunology data set to better detect, diagnose and treat disease. [crunchbase.com, May 15, 20]
Dyno Therapeutics (Cambidge, MA; no SBIR) emerged from stealth with Novartis and Sarepta Therapeutics as partners. The biotech’s technology designs superior versions of the viruses commonly used in gene therapies. Financial terms weren’t disclosed. [Sarah de Crescenzo, xconomy.com, May 11, 20]
Travecta Therapeutics (New York and Singapore, no SBIR), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain-barrier, announces today it has secured US$15 million in its Series A round of financing ... Travecta's mVECTATM proprietary platform is built upon a deep understanding of the Mfs2da transporter protein and its function at the blood-brain-barrier as well as in other key physio-pathological conditions discovered by Dr. David Silver, Professor at Duke-NUS and Scientific Founder of Travecta. [company press release, May 12, 20]
Thermedical (Waltham, MA; $8M SBIR), which is developing a proprietary thermal ablation therapy, raised $7.9M in debt in a $9.5M funding round, according to an SEC filing. [BostInno, May 14, 20]
Some truth from the doc. Bob Wachter,chair of the [UCSF] department of medicine, sets aside at least two hours to keep informed: his Twitter [now 64,000] followers [as part of a growing group of scientists and public-health officials drawing large audiences on social media [to] provide credible information online and steer the conversation away from dubious claims, such as those in “Plandemic,” [Georgia Wells, Wall Street Journal, May 15, 20]
Ultimately, the Chinese are competing to become the world’s leading innovators, and the United States is not playing to win. [Eric Schmidt, ex-chair Alphabet, quoted by Naomi Kein, The Guardian, May 13, 10]
Faster, faster, but how? The president named a former pharmaceutical executive and a retired general to lead a crash development program that if successful would shatter speed records for vaccine development. [NY Times, May 15, 20] Left unsaid: what will they do, and who will pay for it? With something like 100 labs already chasing the golden prize with both public and private money to find a vaccine and manufacture it in a competitve race. At least three each have multi-hundred million dollars committed.
Federal R&D spending has fallen to a mere 0.6% of GDP. Whereas America once led the world in the share of our economy invested in R&D, we now rank 12th globally. [Sen. Chuck Schumer (D-NY), Sen.Todd Young (D-IN), Rep. Ro Khanna (D-CA) and Rep. Mike Gallagher (R-WI),, USA Today, May 14, 20] Everybody has a great idea of what government can and should do, but few poliicians have the courage to stand for the taxes needed to pay for it.
Building and isolating. The Trump administration said it would impose export restrictions designed to cut off the Chinese telecom-equipment maker from overseas suppliers, threatening to ignite a new round of U.S.-China economic tensions. [Bob Davis and Katy Stech Ferek, Wall Street Journal, May 16]
Imara up 20% [May 14, 20]
CytomX Thera down 36% [May 14, 20]
Arcadia Biosciences down 17% [May 14, 20]
FluGen (Madison, WI; $4.3M SBIR) raised $8.18M in debt funding from a total of 47 undisclosed investors, according to an SEC filing. ... currently working with the University of Wisconsin-Madison and India-based Bharat Biotech to develop and test a vaccine for Covid-19. [WiscInno, May 14,20]
AeroVironment landed a potential three-year, $146M contract to provide loitering missile systems designed to help military users reach targets for operations beyond line of sight. The company said Thursday it will start to deliver the Switchblade miniature aerial missiles to the service branch beginning in September under the sole-source contract with a $75.9M base value awarded by the Army Tactical Aviation and Ground Munitions project office due to "joint urgent operational need." Switchblade can be deployed from a six-pack launch platform and seeks to help warfighters hit a target up to six miles from a fixed or a mobile location. The contract includes two option years that would extend work through April 2023. [Nicholas Martin, govconwire.com, May 14, 20]
C2N Diagnostics (St. Louis, MO; no SBIR) received a $20 million Program-Related Investment from GHR Foundation, an independent global philanthropy. [to] position C2N’s Alzheimer’s blood test for entry into the clinic. [company press release, May14, 20]
ReAlta Life Sciences (Norfolk,VA; $800K SBIR, founded 208) prepares to transition into a clinical-stage organization later this year, the Norfolk-based biotech startup closed a $14 million series A2 to support this critical transition [and[ brings the total Series A to $26 million, ... building a technology platform that features a family of over 160 engineered peptides, or short strings of amino acids that are considered the building blocks of proteins. [Will Flanagan, DC Inno, May 5, 2020]
“The cupboard was bare,”[Trump] told ABC News last week. Asked why he more to replenish the stockpile, Mr. Trump said he had been busy, citing the Russia investigation and his impeachment trial. President Obama requested more funding for the stockpile, but his request was rejected by fiscal hawks in Congress. [Rebecca Ballhaus, Wall Street Journal, May 14, 20]
"an angry disgruntled employee who frankly according to some people didn’t do a very good job,” Trump told reporters. [Morgan Chalfant, The Hill, May 14, 20] Evidence? none offered, as usual, for "according to some people." Trump does it week and week out as he avoids showing competent evidence for his claims, such as suggested the coronavirus testing may be "overrated."
We got ours: tax cuts for corporations and the wealthy, bailouts of corporations and financiers. Now "we" can't afford to help the 36 million unemployed with more public debt. How long can the Trump base stand to get nothing for their loyalty?
Australia and China are openly sparring over China’s handling of the coronavirus epidemic, in a sign of how Beijing’s efforts to extend its global influence are backfiring even in places where it is an economic lifeline. [Wall Street Journal, May 14, 20] Lying and evasion can only go so far before the audience demands truth. But politicians and corporate executives seem to first try evasion and denial before being dragged into truth, usually by an alert press.
Infinera down 255 [May 13, 20]
Capricor Therapeutics down 165 [my 13, 20]
Apellis Pharmaceuticals (Waltham, MA; no SBIR) a global biopharmaceutical company pioneering targeted C3 therapies, today announced that it had entered into subscription agreements with a number of institutional investors for a private placement of $300.0 million aggregate principal amount of 3.500% convertible senior notes due 2026 [company press release, May 7, 20]
Trump to visit medical distribution company in Pennsylvania, where he is pressuring the governor to reopen more quickly. [WashPo, May 14, 20] Damn the torpedos, full speed ahead. [Admiral Farragut, 1864] Trump undercuts his case by refusing to recognize and plan for the scientifically established dangerous realities. As if his will alone will cancel them.
Misplaced faith. The Abbott coronavirus test hailed by President Trump and used by the White House failed to detect infected samples in a large number of cases [25% false negatives] [Carolyn Y. Johnson and Steven Mufson, WashPo, May 13, 20]
McConnell’s claim that Obama left behind no ‘game plan’ for the coronavirus outbreak [is wrong] [Glenn Kessler, WashPo, May 13, 20] and irrelevant. Trump has had three years to fix any planning problem. Apparently he is fixated on the present and confident that he can fix any future problem when it happens. A truly magnificent president in his mirror.
Novavax up 53% [May 12, 20] announced that the Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million of additional funding, on top of $4 million it invested in March, to advance clinical development of NVX-CoV2373, Novavax' coronavirus vacccine against CoVid-19. [company press release, May 11, 20]
Nanoviricides up 28% [May 12, 20] announced that it has developed drug candidates that have demonstrated very high anti-viral effectiveness in cell culture studies against multiple coronaviruses. [company press release, May 11, 20]
II-VI up 21% [May 12, 20] reported Record Bookings and Backlog
QurAlis (Cambridge, MA; $200K SBIR), a biotech company focused on developing precision therapeutics for amyotrophic lateral sclerosis (ALS) and other neurologic diseases,announnced the raise of a $42 million Series A financing, bringing the total funds raised to $50.5 million. [company press release, May 13, 20]
Day Zero Diagnostics (Boston, MA; $200K SBIR, founded 2016) an infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections, today announced it was awarded up to $6.2 million in non-dilutive funding [to]support the development of Day Zero’s diagnostic system that is intended to help physicians quickly and accurately diagnose and treat life-threatening bacterial infections. [company press release, May 11, 20]
Kriya Therapeutics (Palo Alto, CA and Research Triangle Park, NC; no SBIR, founded 2019) announced that it has raised $80.5 million in a Series A financing to fund the development of transformative gene therapies for highly prevalent serious diseases. ... focused on developing gene therapies for diseases affecting millions of patients, expanding the field of gene therapy beyond rare monogenic disorders. Kriya is targeting diseases where the underlying biology is well-understood, with the goal of rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate human tissues. [company press release, May 12, 20]
Bristol Myers Squibb and bluebird bio, announced that the companies received a Refusal to File letter from [FDA] regarding the Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pre-treated relapsed and refractory multiple myeloma, which was submitted in March 2020. [companies press release, May 12, 20] With its Bristol Myers-partnered CAR-T therapy under FDA review, bluebird bio is getting a $200 million payout. The Big Pharma is forking over the cash to get out of future payments on the treatment outside the U.S. The duo retooled their deal to focus on the impending U.S. rollout of the anti-BCMA treatment, known as idecabtagene vicleucel (ide-cel) or bb2121, according to a statement. [Amirah Al Idrus, Fierce Biotech, May 11, 20]
AMAG Pharma Cuts 140 Jobs Amid Restructuring, COVID-19 Disruptions [xconomy.com, May 12, 20]
MyoKardia (Brisbane, CA; no SBIR) up 59% [May 11, 20] announced positive topline data from the company's Phase 3 pivotal EXPLORER-HCM clinical trial of mavacamten for the treatment of patients with symptomatic, obstructive hypertrophic cardiomyopathy (HCM) (clinicaltrials.gov NCT03470545). [company press release, May 11, 20]
Quidel up 32% [May 11, 20]
Cytokinetics up 33% [May 11, 20]
Novavax up 31% [May 11, 20] announced that the Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million of additional funding, on top of $4 million it invested in March, to advance clinical development of NVX-CoV2373, Novavax' coronavirus vaccine candidate. [company press release, May 11, 20]
Macrogenics up 29% [May 11, 20]
Bellerophon Therapeutics up 19% [May 11, 20]
Everspin Technologies up 18% [May 11, 20]
BioCryst Pharmaceuticals up 18% [May 11, 20]
AVROBIO up 17% [May 11, 20]
Dicerna Pharma up 17% [May 11, 20]
Immunic up 16% [May 11, 20]
Fluidigm up 16% [May 11, 20]
Capricor Thera up 16% [May 11, 20]
Recro Pharma down 40% [May 11, 20] reported financial results
Moderna announced that the Food and Drug Administration has given them fast-track designation, which is designed to expedite the development of treatments for life-threatening diseases, such as COVID-19. [The Hill, May 12, 20]
OraSure Technologies (Bethlehem, PA; one SBIR in 2012) has a $700 million federal contract to develop a saliva-based antigen test that could be performed at home. The company has antigen tests for other viruses — including HIV and Ebola — and those have accuracy rates of over 95%. Along with accuracy, the company is focused on speed, aiming to delivers results in 20 to 30 minutes. [AP, May 11. 20]
Years before the Covid-19 pandemic, the billionaire [Bill Gates] tried to warn global leaders of the threat from new infectious diseases. Few listened. ‘I feel terrible.’ [Betsy McCay, WSJ, May 11, 20] World's richest man, college dropout, donated tens of billions to his foundation to attack diseases ignored by rich-world nations.
Protagonist Therapeutics (Newark, CA; $3.2M SBIR) up 84% [May 8, 20] announced initial data from the ongoing Phase 2 study of PTG-300 in patients with polycythemia vera. The current results demonstrate that treatment with PTG-300 at individualized doses ranging from 10 mg to 80 mg for up to 28 weeks provided dose-related control of hematocrit levels and eliminated the need for phlebotomy in all six out of six patients that received the dosing as per protocol. [company press release, May 7, 20]
Everspin Tech (Chandler AZ; $600K SBIR) up 52% [May 8, 20] announced unexpectedly higher revenue
BioCryst Pharma up 20% [May 8, 20] announced financial results
CytomX Thera up 16% [May 8, 20]
Quidel (San Diego, CA; one SBIR in 2004), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received Emergency Use Authorization (EUA) from [FDA] to market its Sofia® 2 SARS Antigen FIA, a rapid point-of-care test to be used with the Sofia 2 Fluorescent Immunoassay Analyzer for the rapid detection of SARS-CoV-2 in nasal or nasopharyngeal specimens from patients meeting the Centers for Disease Control and Prevention’s (CDC) criteria for suspected COVID-19 infection. [company press release, May 9, 20]
Boston Dynamics [Waltham, MA; $5.4M SBIR)’ Spot is patrolling a Singapore park to encourage social distancing. In a new pilot program, a remote operator will control Spot as it patrols around two miles of Singapore’s Bishan-Ang Mo Kio Park. A recorded message encourage social distancing will be broadcast from the robot. [Brian Heater, TechCrunch, May 8, 20] The park is a Lush 153-acre urban park along the banks of a former canal with lawns, walking tracks & playground. [park website] where the daily high is 88F in a stable well organized city-state island where hundreds of ships idle offshore awaiting their turn into the port.
Nearly two weeks after the federal government relaunched its small-business aid program with an additional $310 billion, more than 40% of the money remains available. [Wall Street Journal, May 9, 20
On our own. as we try to gauge the dangers, we’re pretty much on our own. The government has been a wildly inconsistent, if not wholly incompetent, counselor in these difficult moments. President Trump has both led the national response and encouraged insurrection against it, while extruding misinformation volcanically. Public health officials on the White House coronavirus task force are routinely forced to do misinformation control. The Centers for Disease Control and Prevention is a treasured institution filled with expertise, but it hasn’t held a news briefing since early March. Governors go their own way, as if entitled to their own epidemiological truths. [Joel Achenbach, WashPo, May 10, 20]If only. “We’re going to do something very fast, and we’re going to have a phenomenal year next year.” The president predicted the virus eventually would disappear even without a vaccine — a prediction at odds with his own science officials. [Josh Dawsey, Ashley Parker, Philip Rucker and Yasmeen Abutaleb, WashPo, May 10, 20]
Fluidigm up 18% [May 7, 20]
Macrogenics down 18% [May 7, 20]
Moderna announced that [FDA] had cleared its application to proceed to a clinical trial involving about 600 people. The main goal of this set of tests is to find out if the vaccine is safe and if positive results from the first few dozen volunteers in the first phase can be replicated in a much larger group. [Knvul Sheikh, NY Times, May 8, 20]
PTC Therapeutics (SOUTH PLAINFIELD, N.J; $6M SBIR) announced that it has entered into an agreement to acquire Censa Pharmaceuticals (WELLESLEY, MA; no SBIR), a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria (PKU) and other diseases associated with defects in the tetrahydrobiopterin (BH4) biochemical pathways diagnosed at birth. PTC will pay an upfront consideration of approximately $10 million in cash and up to 850,000 shares of PTC common stock. In addition to the upfront payments, potential future consideration includes $217.5 million in development and regulatory milestones for the two most advanced programs and receipt of a priority review voucher, including $30 million to be paid in either cash or PTC common stock at our option for completing the enrollment of a Phase 3 clinical trial for CNSA-001 for PKU, $109 million in development and regulatory milestones for each additional indication of CNSA-001, net sales milestones up to an aggregate amount of $160 million and a contingent value payment of a percentage of annual net sales ranging from single to low double digits. [PTC press release, May 6, 20]
Defense Logistics Agency has awarded Intuitive Surgical a potential five-year, $420M contract to provide surgical robots and related equipment to service branches and federal civilian agencies. [Brenda Marie Rivers, govexec.com, May 8, 20]
Macrogenics up 231% [May 6,20] the biotech company's management said it remains on track to report final overall survival (OS) data for the phase 3 SOPHIA study of margetuximab in HER2-positive metastatic breast cancer this year. If the data is solid, MacroGenics believes it could get a Food and Drug Administration decision as soon as December 2020. [Motley Fool, May 6, 20]
Ventus Therapeutics (Waltham, MA; no SBIR) announced a $60 million Series A financing .. to advance three pipeline programs and to expand the company’s structural immunology platform to pursue previously intractable drug targets. [company press release, May 6, 20]
Admin shelves CDC guide to reopening country [JASON DEAREN and MIKE STOBBE AP, May 7, 20] as Fears of ‘second wave’ hang over coronavirus successes [JILL LAWLESS, ELAINE KURTENBACH and CARLA K. JOHNSON, AP, May 7, 2020] Don't let our experts tell them how, let them guess, so we can blame them when it goes wrong?
A man of money, not of people. The president’s cure-can’t-be-worse-than-the-disease logic is clear: As bad as the virus may be, the cost of the virtual national lockdown has grown too high. [Peter Baker, NYTimes, May 7, 20] Fortunetely on the at question, he is only an advisor to states and cities, since he punted on being a supply source. After all, his base includes a lot of money he has already paid off with a new tax law. Interestingly to limit the bad news of more eaths and illness he advocates less testing which correlates with his lackluster support of helping tates with a huge expanse of testing. If you don't want the answer, don't ask the question. A major barrier to agreement is that no one wants to tackle the controversial question of the monetary value of a human life.
news and views about government programs, politics, attitudes ...1996-1997; 1998; 1999; Y2K; 2001 , 2002-2003 ; 2004-5; 2006; 2007-08 2009-2010; 2011-2012; 2013-14 ; 2015; 2016; 2017-18; 2019-20
BMDO/ MDA including SBIR the doings of star wars
Miscellaneous Stories 1996-1997; 1998-1999; 2000-2001; 2002-2003 ; 2004-5 ; 2006; 2007 2009-2010 ; 2011-2012; 2013-2014; 2015; 2016; 2017
IPO and Venture Markets 1996-1998 .... 1999-2005 ... 2006-present
Quotes steal them if you like
Note: in these old stories, many links are dead, obsolete, or missing
Stories about companies; 1-Al .. Am-Az .. B .. C ... D-E .. F .. G-H .. I-J .. K-L .. M ... N-O ... P ... Q-R .. S1-Se .. ... Sf-Sz .. T-U .... V-Z
10 Kardiac Devices .... 10X Genomics ..... 1366
Technologies ... 1st Detect ...
21-Century Silicon ... 21st Century
Systems .... 23andMe ... 24M Technologies
... 30
Second Software ... 360fly ..... 3Bar Biologics .... 3C Semiconductor
... 3DEO .... 3D Glass Solutions ..... 3Dnamics ..... 3D
Robotics .... 3D Systems
..... 3D Technology
Laboratories
.... 3F ... 3iNanotech .... 3PrimiR ...
3Scan ..... 3-V
Biosciences
.... 3VR ... 410 Medical Innovation .... 454 Life Sciences .... 4C
Medical Technologies .... 4D Molecular Therapeutics ..... 4s3
Bioscience ... 5D Robotics
..... 7AC
Technologies ... 89Bio ... 908Devices ... 9Mile Labs
A10 Networks ... A123Systems ... A4 Pharma .... A&G
Pharmaceutical ... Aastrom
Bioscience
.. Abacus Technology ... ... Abaxis .... Abcombi Sciences
.....
Abeona Therapeutics
..... AbGenomicsInternational ..... Abilitech
Medical ... Abiomed ... Ablative Solutions ....
Ablexis
...... ABL
Technologies .... Abpro
Therapeutics ..... AbSci .... Absorbent
Materials ... Abundant Robotics ..... AbVitro ...
Acadia Pharma ... Acambis
.. Accel Diagnostics ..... Acceleron Pharma
... Accelrys
... Accentia
BioPharmaceuticals ... Accent Therapeutics ..... Accera ....
Access Pharmaceuticals
...
Access
Scientific .... Access Vascular ... Accion Systems .....
Accumetrics
... AccuraGen ..... Accurate
Automation
.. Accuray ... Accuri Cytometers
... Acelerox ....
Acelity .... AcelRx
Pharmaceuticals ...
Acera Surgical .... Acer Thrapeutics .... Acetylon
Pharmaceuticals ... Achaogen ... Achates
Power .....
Achillion
Pharmaceuticals ... ACIST Medical Systems .... Acorda
Therapeutics
... Acorn
Cardiovascular ... Acquia .... AcroMetrix
... AcryMed ...
ActaCell ... Actasys .... ACT Biotech ... Active
Power ...
ActivBiotics
... ActivMedia Robotics .... Acton Pharmaceuticals
...
Actuality... Actuate
Therapeutics .... Acucela ... AcuFocus ....
Aculight
...
Acumentrics ... AcuraStem .... Acutus Medical .... Adamas
Pharmaceuticals ......
Adamis Pharmaceuticals
... Adapteva .... Adaptimmune Therapeutics .... Adaptive
Biotechnologies ..... Adaptive
Computing
... Adaptive
Phage Therapeutics ..... Adaptive TCR ... Adarza BioSystems
.....
Addiction
Therapeutix
...
Addrenex Pharmaceuticals ... Adelor ... Adenosine
Therapeutics
... Adesto Technologies .... Adeza Technologies ... Adherex
Technologies ... Adhesys Medical .... Adial Pharmaceuticals .... Adicet
Bio .... AdiMab
... ADispell ... Adlyfe .... ADMA
Biologics .... Admittance
Technologies
.... Admune Therapeutics ..... Adnexus
Therapeutics ... Adrenergics .... Advanced
BioHealing ... ADS Biotechnology ... Aduro BioTech
.... Advanced Animal Diagnostics .... Advanced Biologics ..... Advanced
Bionics
... Advanced Cell Diagnostics ... Advanced Cell
Technology (now sub to Bio-Techne) ... Advanced Ceramics
.... Advanced
Circulatory .....
Advanced Countermeasures
Systems ... Advanced Diamond
Technologies .... Advanced Electron Beams ...
Advanced Fuel
Research ...Advanced Life Sciences ... Advanced Lighting
Technologies ... Advanced Liquid Logic
...
Advanced Magnetics ... Advanced Photonix ....
Advanced
Programming Concepts ... Advanced Receiver
Technologies .... Advanced Scanners .... Advanced Scientific Concepts
..... Advanced Targeting
Systems
.... Advanced
Technology
Materials.(ATMI) ... Advanced Uro-Solutions ..... AdvanDx ...
Advantic ..... Advaxis ..... Adventrx
... Adverum Biotechnologies ..... Advion BioSciences
...
Adynxx ...... Aegea
Medical ... Aegerion Pharmaceuticals .... Aeglea
BioTherapeutics
Holdings ..... Aerial BioPharma .... Aerie
Pharmaceuticals
... Aerin Medical ..... AerisPhotonics ...... Aerius
Photonics
... Aerodyne Research ... Aero Farms System
... Aerovel ..... AeroVironment ... Aerpio
Therapeutics .... AesRX
...
AETC ... Aethlon Medical
... Aethon .... Aevi Genomic Medicine .....
Affectiva
.... Afferent
Pharmaceuticals ..... Affigen .... Affinia Therapeutics< .....
Affinimark
Technologies
... Affinity BioReagents ... Affinium
Pharmaceuticals ..... Affinivax .... Affomix ....
Affymax ....Affymetrix ... aFraxis ... AgBiome ..... AgeneBio
....
Agennix ... Agenovir ..... Agenus .... Agere
Pharmaceuticals ..... Agile
Materials
... Agile
Planet ... AgileSwitch .... Agile Therapeutics ....
Agility
Robotics ..... Agilis Biotherapeutics .... Agiltron...Agilvax ....
Agilyx ....
Aagios
Pharmaceuticals... AgraQuest .... Agritope... Agrivida
... Agro Biosciences .... Aguila
Technologies.....Ahura Scientific.... Aiko Biotechnology
... Aileron Therapeutics .... Aimmune Therapeutics
(formerly
Allergen Research) ..... airtricity... Airware .... Airxpanders ....
Airway Therapeutics .... ait laboratories... Akadeum Life Sciences ....
Akamai
Physics
Akarna
Therapeutics
..... Akashi Therapeutics ..... Akcea Therapeutics ..... Akebia ....
Akero Therapeutics ... Akermin ..... Akers BioScience ..... Akita
Innovations
... Akouos ....
Akrevia Thera {now Xilio Thera) .... Akron
Polymer Systems ..... Akron Surface
Technologies ..... Akros Medical ....
Alabama
Cryogenics ... Alafair Biosciences .... Albany Molecular
(AMRI) ...A?
nanotech .... Alcon .... Alcresta
.... Aldagen
... Aldatu Biosciences ..... Aldea
Pharmaceuticals
... .
Alder biopharma Aldevon ..... Aldeyra Therapeutics (formerly
Aldexa Therapeutics) .... Alector .... Alexar Therapeutics .....
Alexion
... ....Alexza ....
Alfalight.... Algaeventure Systems ... Algenetix .... Algeternal
.... Algorithmia ..... Alien Technology
.... Alimera sciences.... Alios BioPharma ....Aliva
biopharmaceuticals ..... AliveGen .... Alivio Therapeutics .....
Alkermes...
Alkeus Pharmaceuticals ...
Allakos ... Allcast ....
Allegro Diagnostics ....
Allegro
microsystems ... Allena Pharmaceuticals .... Allergy Amulet
.....
Allerquest
.... Alleviant Medical .... Allied BioScience ..... Allied Minds ....
Alliqua .... Allos
Alloy Polymers .... Alloy
Surfaces .....
Allurion Technologies ... Allylix ... Ally Therapeutics ....
Alnara Pharmaceutical
...
Alnylam... Alper Biotech ... Alphabet Energy .... AlphaCore Pharma ...
Alphamed.... Alphatec
Holdings .....
Alphavax ... Alpine Biosciences .... Alpine Data
Labs .... Alpine Immune Sciences ..... Alseres ..... Algeternal
.... Alta Devices ... AltAir Fuels ... Altair
Therapeutics
... Altamira Technologies .... AltaRock
... AltheaDX .... Althea
Technologies ... Altimmune ..... Altor ...
Altra ...
Altura Medical ... Altus Pharmaceuticals ...
ALung
Technologies
... Alvine Pharmaceuticals .... ALX
Oncology .... Alycone
Lifesciences .... Alzeca ..... AMAG Pharmaceuticals
... Alzheon ..... Amaranth Medical .... Ambarella .....
Amberwave
... Ambiq
Micro ....
Ambit
Biosciences .... AMBP
Technology ... Ambri .... Ambrx ...
Ambry .... Ambys Medicines .... Amendia .... American Bionics .....
American
Gene Technologies International .... American Lithium Energy ....
American Medical Systems ....
American Science and Engineering
... America Stem Cell, now Targagyme .... American
Superconductor
... American XTAL .. Ames
Technology ... Amgen ... Amicus Therapeutics .... Amionx ..... Amnis
...
AMO
Pharma ..... Amphivena Therapeutics .... Ampio Pharmaceuticals .....
Ampla
Pharmaceuticals ... Amplimmune .... Amplyx Pharmaceuticals
.....
Amprius .... ARMO
BioSciences .... Amunix Pharmaceuticals .... Amylin
Pharmaceuticals ... Amylyx ..... Amyris
Biotechnologies ... AN2 Therapeutics .... Anacor
Pharmaceuticals ...
Anadys
Pharmaceuticals ... Anakim Biologics ....
Analog Computing
Solutions .... Analytical Space ..... AnaptysBio
... Anavex Life Sciences .... Anchor Therapeutics ...
Ancora Pharmaceuticals
... AnDAPT ..... Anexon .... Anew Optics ... Angeion ...
AngioDynamics
... Angiologix ... Angstrom Medica .... Angstron
Materials
... Animalgesic Labs .... ANI Pharmaceuticals ...
Animetrics .... Anivax .... Anivive Therapeutics ..... Annexon
Bioscience ..... Annovis Bio .... ANP Technologies
..... Ansoft
... Ansun Biopharma (formerly NexBio) .... Antegrin
Therapeutics
..... Anthera
Pharmaceuticals .... Anthos Therapeutics .....
Antigenics ... Anue Systems ... Anulex Technologies
... Anybots ... AOBiome Therapeutics
(formerly
Nitrocell) .... AOptix Technologies
... Aortica ..... APA
Optics (Enterprises) ... Apellis Pharmaceuticals
.....
Apexigen ... Aperiomics .... Aperion Biologics .... Aphios
... Apic Bio .... Apieron ... Apnex Medical
... ApniCure .....
ApoCell ....
ApoGen Biotechnologies .... Apollo
Diamond
... Apollo Endosurgery ... Apollomics
(previously CBT
Pharmaceuticals) .... Apoplogic Pharmaceuticals
... Applied Biomolecular Technologies .... Applied Biosystems
.... Applied Defense Solutions ..... Applied DNA
Sciences .... Applied Genetic Technology ... Applied Nanotech
....
Applied
NanoWorks ... Applied Optimization ..... Applied
Optoelectronics ... Applied Physical Electronics ...
Applied Physical Sciences ... Applied Precision ..... Applied
Proteomics ..... Applied Quantum Technologies .... Applied Quantum
Technology
.... Applied Research Associates
... Applied
Science and Technology ... Applied Signal
Technology
... Applied Therapeutics ...... AppThwack ....
Aprea Therapeutics .... Aprecia Pharmaceuticals ....
Apricus
Biosciences
... APS BioGroup .... Apse .... Aptalis Pharma .... Aptevo
Therapeutics .....
Aptima ... AptamiR
Therapeutics .... Aptinyx .... Aptose
Biosciences .... Aptus
Endosystems ... Aquaback Technologies ...
Aqua Bounty
... Aquacue .... AquaHarmonics ..... Aqua Metals .... AquaMost
...
Aquarius
Technologies ... Aquestive Therapeutics ....
AqueSys
... Aqueti .... Aquion .... Aradigm ....
AragonPharmaceuticals
...
Aratana
Therapeutics ..... Arbor Biosciences< ..... Arbor Biotechnologie
..... Arbor Pharmaceuticals
...
Arbovax
... Arbutus BioPharma (formerly OnCore) ..... Arca Biopharma ....
Arcadia Biosciences ..... Arcadia Pharma ..... Arcantatura...
Archemix
... Arcellx .... ArcherDX ......Arch Innotek ..... Arch
Oncology ..... Arch
Therapeutics
... Arctic Sand Technologies .... Arcturus Therapeutics ....
Arcus Biosciences ..... Arcutis Biotherapeutics .... Ardea Biosciences
...
Ardelyx .... Ardian .... Arena Pharmaceuticals
... Argentum ..... Arginetix
... Argo AI ..... ArgonST ... Argos Therapeutics ... Aria CV
...
Ariad Pharmaceuticals .. Aria Insights (previously CyPhy
Works) .... Ariosa Diagnostics ..... Arista MD
....
Arista Networks .... ARIZ Precision
Medicine .... Arkansas Power Electronics ..... Arkuda Therapeutics ...
Armadillo Aerospace
... Armata
Pharmaceuticals .... Armetheon .... ARMO BioSciences .... Armonica
Technologies .... Armorworks
... Armune BioScience ..... Aro Biotherapeutics
.... Aronora ..... Arpeggi
.... ArQule ... Arrakis Therapeutics .....
Array ... Arranta Bio .... Array Information
Technology ..... Arresto
Biosciences .... Arrien Pharmaceuticals ... Arrivo
BioVentures ..... Arrowhead Pharmaceuticals ..... Arrowhead
Research .... Arsanis ... ArsenalBio ...
Arsenal Medical
.... Arstasis ... Artel .... Arteriocyte
... Arterys
..... ArthroCare
...
Arthrosurface ... Artisan Pharma ... Artizan .... Artrility
Medical ..... ArunA Bio .... Arvegenix ..... Arvinas .... Arxan
Technologies .... Aryx
Therapeutics ..... Aryx
... Arzeda
... Asana Medical (now Regentsys) .... Asante Solutions .....
Ascelegen
Therapeutics .... Ascension
Orthopedics ... Ascent
Solar Technologies ....
Ascent
Therapeutics .... AsclepiX Therapeutics .... Aseptia .... Ash
Access Technology .... Asklepios
Biopharmaceutical .... AstroWatt .... Aspen Aerogels
.... AspenBio
Pharma .... Aspen
Neuroscience .... Aspen Products Group ....
Aspen Technology
... Aspyrian Therapeutics .... Assurex Health ..... Astex
Therapeutics ...
Asthmapolis .... Astralux
... Astrobotic Technology ....
Astronautics Corp. of
America ... AstroPower... AstroTerra ..
Astrum Solar ... Astute
Medical ....
Astute Medicales ... Asuragen
... Atacama ..... Atara Biotherapeutics ..... Ataxion ....
Athenex
(formerly
Kinex) ..... Athenix
... Athens Research ..... AtheroGenics ... AtheroMed ....
Athersys .... ATI Industrial
Automation
... Atlantia ... Atmocean .....
Atmospheric Glow
Technologies ...
Atomate ... Atomic Medical Innovations .....
Atomometrics
... Atomwise ..... Atoptix .... Atossa
Genetics
... Atreaon ....
Atreca .... Atreon Orthopedics
..... AtriCure ... Atrium
Medical ... ATRP Solutions ... aTyr Pharma .....
Audentes
Therapeutics ..... Audience
... Augmenix
.... AUM
Cardiovascular ... Aura Biosciences ....
Auris Health .... Auris Medical .... Auris Surgical Robotics
..... Aurora
Algae ... Aurora Flight
Sciences ....
Aurora
Imaging Technology ...
Aurora Spectral Technologies
... Auspex
Pharmaceuticals ... Ausra ... Auterra
.... AuthenTec .... Autolus Therapeutics .... Automated Dynamics ...
Automated
Medical Instruments .... Autonet ... Aushon
Biosystems ... AutoGenomics .... Autonomic Materials
.... Autonomic Technologies ..... Autonomous Technologies
....
Auxilium
Pharmaceuticals ... Avalanche
Biotechnologies .... Avalyn Pharmaceuticals .... Avanir Pharmaceuticals
... Avant Immunotherapeutics ... Avanti Metal ...
Avaxia
Biologics ... Avedro ... Avelas Biosciences ....
Aveo
Pharmaceuticals
... Avery Therapeutics ..... AveXis .... Aviation Resources
Delaware .... AVI
BioPharma ... Avici Systems ... AvidBiotics
.....Avidity
Biosciences .... Avid
Radiopharmaceuticals
... Avila Therapeutics ... Avinger ....
... Aviragen Therapeutics (formerly Biota
Pharmaceuticals)
..... Aviron ..... Avisa Pharma .... Avita Medical Americas .....
Avitude .... Avrobio
..... AVT Simulation .... Aware ... Axcella Health (was Pronutria)
.....
Axelo .... Axerion Therapeutics
... Axial
Biotech .... Axial Biotherapeutics ..... Axion BioSystems
.....
Axion Power
... Axis Clinicals .... Axis
Semiconductor
... Axium Nanofibers ...... Axium Pharmaceuticals .... Axogen
.... Axonia Medical ....Axonics Modulation Technologies
Axsome Therapeutics ..... Axsun Technologies ... Ayasdi
..... Azaya
Therapeutics ... Azelon Pharmaceutical ... Azimuth
.... Azitra ..... Aziyo Biologics ..... Azure Biotech ..... AzurRx
BioPharma
Baby Genes .... Bacterial Robotics .... BacterioScan ....
Baebies
..... Bagaveev
.... Ballard
Power ... Bamboo Therapeutics ..... Bandgap ... Banner Life
Sciences ..... Banyan Biomarkers ... Bardy
Diagnostics .... BarioSurg ..... Baryonyx .... Barrier
Therapeutics ... Baseload Renewables .... Basis
Science
.... Bastion
Technologies
.... Batu Biologics ..... Bauhaus Software ..... Baxano ...
Baxano Surgical .... BayoTech ..... Beacon Biomedical ..... Beacon
Power ... Beam Therapeutics ..... Beat
Biotherapeutics .... Beeco
... Behavioral Recognition Systems .... Bellerephoon
Tera .... Bellicum
Pharmaceuticals .... Belmont Instrument ....
Benchmark
Automation ... BeneChill
... Benefuel ... BeneVir Biopharm ....
Bennett
Aerospace .... Benson Hill
Biosystems ..... Benvenue
Medical .... Berg .... BerrieHill
Research
... BESS Technologies .... BetaBatt
...
BetaLED ....
LEDBG Medicine
... Bettergy .... Bexion Pharmaceuticals .... Bina
Technologies .... Bind
Bioscience ... Bind Therapeutics .... BinOptics ..... BiO2
Medical
... BiO2
Technologies
...
BioAmber ... BioAdvanTek ... BioAffinity
Technologies .....
Bioanalytical Systems
... BioBehavioral Diagnostics ... BioBridge
Global
..... BioCardia .....
BioCentra Molecular Innovations ..... Biocept
...
BioChemics ..... BioClin Therapeutics .... Bicycle Therapeutics .....
Bien-Etre
Labs ..... BioCold Genesys .... Bioconnect Systems .... BioConsortia
..... BioCritica
... BioCryst Pharmaceuticals ...
BioDelivery Sciences ... Biodesix .... BioDirection ..... BioDtech ...
BioFactura ... ..... BioE ...
BioFire .... BioFluidica ..... Biogenic
Reagents
.... BioGreenChoice ... BioHaven Pharmaceuticals ..... Bioheart
...
Biohelix ... Bio-Imaging Technologies
...
Bioincept .... Biointervene .... BioKier ..... Biolex Therapeutics
... BioLife4D ..... BioLink Life
Sciences
... Biolinq (formerly Electrozyme) .... Biologics
...
BioMagnetic Solutions ....
BioMarin
Pharmaceutical
... BioMarck
Pharmaceuticals .... bioMASON ..... Biomatrica ...
BioMedical
Enterprises
... Biomedical Sciences ..... Biomedical
Structures ...
BioMedix .... Biomeme .... Biomerica .... Biometric
Signature
... BioMimetic Therapeutics
... BioMotiv .... BioNano
Genomics ... BioNanomatrix ... Bionostics
Holdings
... Bio-Path Holdings ..... Biophan Technologies
... Biophysical ... BioProcessors ...
Bioptigen
... Bioptix .... BiOptix Diagnostics ..... BioPulping
International
...
Biopure ... Biorasis ..... BioRelix ... BioResource
International
...
BioRestorative Therapies (formerly Stem Cell Assurance) ....
BioSante Pharmaceuticals ... BioScale
.... BioSense
Technologies ... BioSensics .... BioSentinel
Pharmaceuticals
... BioSig Technologies ..... Biosortia Pharmaceuticals ....
BioSphere Medical
.... Biostage (formerly Harvard Apparatus
Regenerative
Technology) ..... BioStructures .... Biosurfaces .... Biosym
Technologies later Accelrys
....
BioSystem
...
Biota Pharmaceuticals .... Bio-Techne ..... BioTechnique ....
BioTechPlex .....
Biotectix
....
Biotel
.... BioTelemetry (formerly CardioNet) ..... BioTex
....
Biothera
... BioTheranostics ... Bio Time ...
Biotix
... Biotronic NeuroNetwork ..... Biotronik ....
BioTrove
... BioVaxys .... Bioventus ..... Biovest International ....
BioVex
... BioVirtua ..... Bird Rock Bio (formerly RuiYi) .....
Birich
Technologies .... Biscayne Neurotherapeutics ..... Bitstream
... Black
Diamond Therapeutics .... Black-I Robotics
... Black Sand ... BlackThorn
..... BladeLogic
... Blasch Precision Ceramics .... Blaze
Bioscience ... Blend
Therapeutics ....
BL Healthcare ... Block Engineering ...
Bloom Energy
... Bloo Solar ..... BluDiagnostics ..... Blue Belt
Technologies
...
Bluebird
bio ...
BluDiagnostics .... Bluefin Robotics ... Bluegrass
Proteins
.... Bluegrass
Vascular
Technologies .... Blueprint
Medicines ...
BlueRock Therapeutics ..... Blue
Sky Batteries ... Bluewater Bio International ... Blue Water
Vaccines .... Bolder Surgical ... Bolt
Biotherapeutics .... Bolt Threads ....
Boom Supersonic ..... Boragen .... Boston Biochem
... Boston Biomedical ... Boston Dynamics
...
Boston Engineering ... Boston Micromachines ... Boston
Micromachines (formally Boston
Electrometallurgical .... Boston-Power
...
Boston
Therapeutics ... Bot Dolly .... Boundless
... Boundless Bio ... BoXZY
..... Braeburn Pharmaceuticals ..... BrainCells
... BrainScope .... Brain Sentry ....
Brain Tunnelgenix
Technologies .... BrainXell ..... Branch Medical Group ..... Brayton
Energy
.... Breathe
Technologies ... Breethe .... Breonics ...
BreviTest
Technologies
..... Brewer
Science ... Brickell Biotech .... Bridger Photonics .... Bridgelux
... Brightsource Energy ... Bright View
...
Brimrose Corp of America ... Briteseed .... Brock Rogers Surgical
...
Bromium
.... Brooks
Automation ...
Bruker Daltonics .... Buffalo BioLabs ..... Burl
Concepts
..... Burr Oak
C12 Energy ... C2Sense .... C3Nano
... C4 Therapeutics .... C8
Sciences ....
C9 ... Cabaletta Bio .... CABG Medical ....
Cadence Pharma ....
CadheRx
Therapeutics
.....
Caisson Biotech .... Calabazas
Creek
Research .... Caladrius
Bioscience ... Cala Health ..... Calando
Pharmaceuticals
... Calbiotech .... Calera ... Caliber Biotherapeutics ....
Calibra
Medical ... Calient ... California Wave Power
Technologies ..... Calimmune ..... Caliper Life Sciences
....
CaliSolar ... Calistoga Pharmaceuticals ...
Calithera
BioSciences .... Calixa
Therapeutics ... Callidus Biopharma ... Calporta
Therapeutics
.... Calspan .... Caltech Metals ... Calysta .... Calyxt ..... Cambrian
Innovation ... Cambridge
Endoscopic Devices ... Cambridge Heart
.... Cambridge
Research & Instrumentation ... Cambrios
Technologies .... CAMX ..... Candela Laser ....
Cancer
Genetics .... Cancer Prevention
Pharmaceuticals .... CanDiag .... Canopy Biosciences ..... Capesym
... Capillary
Biomedical ..... Capio Biosciences .... Capnia
... CAPP Medical ..... Capricor Therapeutics .... Cara
Therapeutics .... Carbon .....
Carbon
Design
Systems ... Carbtex Technology
.... Carbylan Therapeutics ..... Cardeas
Pharma ....
CardiacAssist ..... Cardiac Concepts ...
Cardiac
Dimensions
... Cardiac Science ..... Cardialen ..... CardiAQ Valve
Technologies ... Cardica
... CardioDx
... Cardio Flow ..... CardioFocus ... CardioInsight
Technologies .....
Cardiokinetix ..... CardioMag ... CardioMEMS .... Cardionomic ....
CardioNXT ..... Cardiorobotics
...
Cardiosolutions ... Cardiosolv .... CardioSpectra ... CardioTech
... Cardiovate ..... CardiOx ...
Cardioxyl
Pharmaceuticals
.... CareDx (formerly XDx) .... Caribou Biosciences
.....
Carigent Therapeutics .... Carisma Thera (formerly CARMA Therapeutics)
..... Carlsme .... Carmot Therapeutics
..... Carnegie Robotics
.... Carnegie Spee .... ... .... Carnot BioSciences ....
CaroGen .... Carter Aviation Technologies .... Carticept
Medical ... Cartiva ..... Cascade Designs ...
Cascade
Microtech
... Cascadian Therapeutics (formerly Oncothyreon) ..... Casma
Therapeutics .... Castle Pharmaceuticals .... Castle Creek
Pharmaceuticals
Catabasis Pharmaceuticals ... Catadon
Systems ... Catalyst Biosciences ... Catalyst Pharma
.... Catalytic Innovations ..... Catalyze ..... Catelectric
.... Cebix .... Cedarburg Pharmaceuticals .... Cedilla
Therapeutics ..... CeeTox
... Celadon ... Celator Pharmaceuticals
... CelcuityCeldara Medical ..... Celladon .... Cellara .... Cell Care
Therapeutics ..... Cellceutix
.... CellCyte
Genetics ... Cell Design Labs ..... Celldex Therapeutics
... ..... Cellectar ... Cellerant
Therapeutics
... Celleration .... Cell Genesys ... CellRight
Technologies
..... Cellular
Bioengineering
...
... Cellular Bioengineering ..... Cellular Biomedicine Group
.....
Cellular Dynamics International .... Cell>Point
.... CellSavers ..... Cellscape .... Cellscript
..... Cell
Signaling Technology ...Cell
Therapeutics (now CTI
BioPharma)
... CellTraffix ... CeloNova Biosciences
..... Cel-Sci
.... Celsion ...
Celtaxsys ..... Celula..... Celularity ..... CellzDirect ...
Cempra Pharmaceuticals.
.... CeNeRx
BioPharma ... Centocor .... Centrexion Therapeutics .....
Centrose ... Centice .. Century Therapeutics .... Centritec
Seals ... Cephalon
... Cepheid
... Cephalon ... Ception Therapeutics
... Cequent
Pharmaceuticals ... Cerebras Systems ..... Ceradyne ...
Ceramic
Tubular Products .... Ceramitron ... Cerapedics
.... Ceramatec
... Cerevast Therapeutics .... Cerealus Holdings
... Cerebral
Therapeutics .... Cerecor .... Ceregene ...
Cerahelix
.. Ceres Nanosciences ..... Cerevance .... Cerexa
.... Cerion
Enterprises ...
Cermet ... Cernostics ..... Cerulean Pharma
... Cerus ... Cervel Neurotech .... Cesca
Therapeutics .... Ceterix .... Orthopaedics ... CFD Research ..
CFX Battery
.... CGI Pharmaceuticals ... ChaCha
... Chantilly BioPharma .... Chapman
Innovations ... Charles River Analytics .... Charles
River Lab ... Charter Medical ..... Chase Therapeutics ....
CHASM
.... Chatham
Therapeutics ..... Checkerspot ..... Chemat ... Chembio Diagnostic
Systems .... ChemImage ... Chemir Analytical
Services ...
ChemoCentryx
... Chemtura ....
Chesapeake Sciences
...Chesson Labs ... Chiasma .... Chimera
Bioengineering ..... Chimerix
... Chlorogen ... Choice Therapeutics
... Chondrogenics
... Chordia
Therapeutics .... Chorum Technologies
.... ChromaCode
..... ChromaDex
..... Chronix
Biomedical
... Chrysalis BioTherapeutics .... Cibus
Global
... Cidara Therapeutics .... Ciena
....Ciencia ...
Cilion .... CimaBay Thera ..... CinCor Pharma .... CinRx ....
Ciranova
... Circle
Technologies ..... Cirius Therapeutics ..... CivaTech
Oncology ... Civetta Therapeutics .... .... CiVi Biopharma .....
Civitas Therapeutics
..... Claret Medical .... Clarassance ..... Claresta
Solutions
.... Clark-MXR ...Claros
Diagnostics
.... Clean Diesel
Technologies ... Clear Catheter Systems .... ClearCount
Medical
Solutions .... ClearEdge
Power .... Clear Guide Medical .... Clearside
Biomedical ... Cleave Biosciences ... Cleveland BioLabs ...
Cleveland
Polymer Technologies ..... CleverSet ... Clinical Data
... Cloudant ... CloudMade ... Cloud
Pharmaceuticals
(formerly Teradiscoveries) .... Clovis
Oncology ... Clovis Tech ..... CMC Biologics .... C-Motive Technologies
.... CoAdna,Holdings ..... CoAxia ....
Cobalt Biofuels ... Cocoon Biotech .... Cocrystal
Discovery ... Coda
Biotherapeutics .... Codexis
... Co-Diagnostics< ... Codiak
BioSciences ..... Codon
Devices ... Co-D Therapeutics .... Cofactor
Genomics ....
Cogenra .... Cogentix Medical ..... Cognex
...Cognition
Therapeutics .... Cognitive Code
... Cohera
Medical .... Coherus Biosciences .... Cohesive
Technologies ... ColdQuanta .... ColdWatt ... Collagenex
Pharmaceuticals ...
Collegium Pharmaceutical ... CoLucid Pharmaceuticals
... Columbia Labs ..... CombiMatrix ...
CombinatoRx
..... Combined Energies .... Combinent
BioMedical Systems ... Comet Therapeutics .... Comfort Motion
Technologies
...
Commonwealth Biotechnologies ... Commonwealth
Fusion Systems ..... Compact Membrane Systems ...Compass
Therapeutics .... Compellent Technologies ... Compendia
Bioscience
.....
Complete
Genomics ....
Complexa
..... Conatus
Pharmaceuticals ... Concert
Pharmaceuticals
.... Concordia Fibers ...Concurrent Technologies ...
Conductus
.. Confluence Life Sciences ..... ConforMIS ...
Cognigen
.... Conispire
.... ConjuGon .. Connecticut
Valley Bindery ... Consonus Technologies
...
Constellation
Pharmaceuticals .... Context Therapeutics ..... Contour Energy
Systems ControlRadSystems ..... Convelo
Therapeutics ....
Conventus
Orthopaedics ..... Convergen
... ConverGene .... Convio .... Convoy
Therapeutics
.... Cool-Bio
.... CoolCAD Electronics .... CoolChip Technologies
....
Cool Earth
Solar
.... Cooligy ... CoolTech .... Corbus
Pharmaceuticals
..... Corcept
Therapeutics
...
Cordex Systems .... CoreStreet ... CoreTek ...
.Corgenix
Medical
... Corindus ....Corinthian
Ophthalmic ... Corium International .... Corixa
....
CorMatrix
Cardiovascular
.... Cormedix ... Cornami ..... Cornerstone Research
... Cornerstone BioPharma then Cornerstone
Therapeutics
..... Cornerstone Therapeutics .... Coronado
Biosciences ... CorQuest Medical ..... Correx ... Corridor
Pharmaceuticals
... Cortana ..... Cortendo AB ..... Cortexyme ....
Corvidia
Therapeutics ..... Corvus
Pharmaceuticals
..... CosmosID ..... CoStim Pharmaceuticals
.... Cougar
Biotechnology ...
Coulbourn
Instruments .... Coulter Pharmaceuticals ... Cour
Pharmaceutical
Development .... Coverity ..... Creare ...
Creative
Hybrid Solutions .... Creatv MicroTech .... Cree
Research ... Crescendo Bioscience .... Crinetics
Pharmaceuticals
....
CrispTek .... Critical Therapeutics .... CritiTech
... Crossbar .... Cross Current ..... CrossFire
... Cruise Automation .... Crux Biomedical
...
CryoCor ...
CryoLife ... Cryomedical Sciences ..... Cryptonite .....
Crystal
IS
...
Crystal Systems ... Crystallume ... CSA
Engineering ... CS-Keys ... CTD Holdings
..... CTI
BioPharma (formerly
Cell Therapeutics) .... Cubist
Pharmaceuticals
... Cue Biopharma .... Cullinan Oncology ..... Cumberland Pharma ....
CuraGen ... Curamir Therapeutics ... Curative .... Current Motor
...
Curtana Pharmaceuticals .... Custom Electronics .... CVD
Equipment ..... CVRx
... CV
Therapeutics ... Cyanotech ..... Cyberdyne .... CyberKey Solutions
... Cyberkinetics Neurotechnology ... Cybernet Systems
... CyberOptics ... Cyclerion
Therapeutics .... Cydan ....
Cygnal
Therapeutics .... Cykloburn
Technologies ..... CymaBay
Therapeutics
.... Cymbet ... CyMedica Orthopedics ..... Cymer
...
Cynosure ... Cyntellect ... Cypher Genomics ... CyPhy Works
... Cypress Bioscience ... Cyrus Biotechnology .....
Cyteir
Therapeutics ..... Cyterix
Pharmaceuticals ...
CytImmune .... CytoBioScience ..... Cytocentrics ..... CytoCore
(formerly Molecular
Diagnostics) ..... Cytocybernetics ..... CytoDyn
.... Cytogel Pharma
.... Cytokinetics
... Cytometix ....CytomX ...
Cytonome
....
Cytori Therapeutics ... Cytophil CytoSolv
... Cytosorbents ..... Cytovas ... CytRx ..... Cytyc
...
CyVek
Fallbrook
Technologies
... Famigo ... Faraday Pharmaceuticals .... Farodox
Energy
Storage
...
FarSounder ... Far-Tech.... FastCAP Systems ...
Fate
Therapeutics
... Fathom .... Fe3 Medical .... FEI ... Femasys
.... Femta
Pharmaceuticals
.... Ferrate
Treatment Technologies ... Ferric Contrast ...... FerroKin
BioSciences ....
Fervo Energy .... Feuz Manufacturing ... FGC Plasma Solutions
..... Fiber and Sensor ....
Fiberight ...
Fiber Materials ... Fibersense ... Fiberstar ....
Bio-Ingredient
Technologies ... Fibertek .... Fibrocell Science
... FibroGen ... Filter
Sensing Technologies ...
Finally Light
Bulb ..... Finch Therapeutics Group ..... FineLine Prototyping ....
Finisar
... Fire Alarm
Specialty Design .....
Firefly
BioWorks ... Firefly Energy .... Firefly LED
...
First Solar ... Fisker Automotive ... Five Prime
Therapeutics .... Flex Biomedical
... Flexion Therapeutics ... Flex Pharma
.... Flextronics
America ....
Flexus Biosciences .... FLIR Systems
.. FloDesign
Wind Turbine ... FlowCardia
...
FlowMedica .... FlowMetric .... Flow Metrix
...
FluGen
... Fluidic Energy ... Fluidigm ... Fluid Innovation
Group
... Fluidnet ... Fluidnet
FluoroPharma
... Fog Pharma ..... Foghorn
Therapeutics .... FokusLabs .... FoldRx Pharmaceuticals
...
Follica ...
Footnote .... Foresight Biotherapeutics .... Forest Devices .... Forge
Therapeutics .....
F-Origin
... Forma
Therapeutics ...
Formlabs
.... For-Robin ..... ForSight Vision5 .... Fortis Therapeutics .....
Forty Seven ..... Forum Pharmaceuticals ..... Forus
Health ... Foster-Miller .... Foundation Medicine
... Fox Chase Chemical Diversity Center ....
Fractal
Antenna Systems ... Fractyl Labs ..... Freedom Meditech
... Free
Flow Power ... Free Form Fibers .... Freenome ..... Froedtert
Health ..... Frontier
NanoSystems ..... Frontier Technology ..... Front Range Biosciences
.... FTL Solar
...
FuelCell Energy
... Fuel Tech
.. Fulcrum Therapeutics ..... Fulgent Therapeutics ..... Full
Spectrum Genetics .... Furiex
.... Fused
Innocation.
...
Fusion
Coolant Systems ... Future Technologies
i20 Therapeutics .... IAP ... IBC Advanced
.... iBiquity Digital ..... Ibis
....
Iblogix
.... IBT
Laboratories
... Icagen .... Icardiac.... Ichor Medical Systems .... Iconic
Therapeutics ..... Icos.... Icosavax ... ICX....
Idaho.... Ideal
Converters ... Ideapaint.... Ideaya Biosciences ..... Idera
Pharmaceuticals ..... ID Genomics ....
Idevices
... IDx ..... iFirst Medical Technologies ...... IFM
Therapeutics
..... Igenica
Biotherapeutics .... IGM Biosciences ..... Ignyta.... Ii-IV
.... Ikaria... Ikonisys... Illinois Superconductor.... Illumigen....
Illumina.... Illuminating Diagnostics ..... Illuminoss....
Illumitex.... Imagen Energy .... Imagevision.... Imaging
Biometrics... Imagineoptix ... Imago Instruments... Imanis
Life... Imara .... Imbed Biosciences... Imetalx... Immco...
Immersion... Immtech...
Immucell .... Immucor ....
Immune... ... Immune... Immune Pharma .... Immunetics...
Immunex...
Immunexcite...
Immuneworks... Immunexpress ..... Immunic ..... Immunicon... Immunitas
Therapeutics ..... ImmunoCellular Thera .... ImmunoChemistry
Technologies ..... Immunocore...
Immunogen... Immunome ..... Immunomedics..... ImmunoMolecular
Therapeutics .... Immunomic Therapeutics
.....
Immunophotonics ... Immurx... .... Immusant...
Immusoft ..... Impact Biomedicines .... Impact Proteomics
.... Impact Science...
Impel
Neuropharma... Imperium Renewables... Impinj... Implant
Sciences... Impossible Foods .... Imprimis Pharmaceuticals .... Imprint
Energy .... Impulse
Monitoring ... Imricor Medical Systems ..... Imris .....
Imthera...
I-nalysis ... Inari Agriculture .... InCarda Therapeutics ....
INCELL .... Incelldx
..... Incitor (now XF
Technologies) .... Incodema3D ..... Incontrol
Research... InCube Labs ..... Incyte ....Incytu... Indalo
Therapeutics ..... Indiana
Nanotech... Indi Molecular ... Industrial Heat ..... Industrial
Perception...
Inentec ... InfaCare Pharmaceutical .... Infarct Reduction
Technologies .... Infinera...
... Infinia... Infinite Electronics .... Infinity... Infinium
.... Inflammatix .... Inform
Genomics... Infoscitex... Inframat... Infraredx... Infrascan... Inf
Robotics ... Infusion Medical ... Ingeneus... Ingeneron .....
Inhibitex... Inhibkase
Therapeutics .... Inhibrx< .... INI
Power... Inland Labs ..... Inmobly .... INmune Bio .... InnAVasc
Medical ....
Inneroptic...
Innerpulse... Innocrin Pharmaceuticals ..... Innography...
... Innopad... Innotec ..... Innovalight...
Innovari Energy Design Microplate Scientific...
pulmonary solutions.... silicon... Innovate Biopharmaceuticals .....
Innovative Spinal...
Innovative... Innoventiontech ... Innovention (now
Ccardiorobotics) ... Innovative Trauma or...
Innovolt ...
Innowave... ... ... Innoviva ...
Innov-x... Inocucor ..... Inorganic Specialists... Inotek...
Ino
.... Inova
Labs
Biomedical... Inovio... Inovise Medical ..... Inozyme Pharmaceuticals
..... Inphase...
... Inphi... Inpria ..... Inscripta ..... Insert MRI...
Insight...
..Insite Vision...... Insitu... InSitu
Biologics ..... Insmed... Inspired Solar Systems ...
Inspire...
Insulet
Labs
... Intact Vascular... Intaglio... Intalio ... Intarcia
Therapeutics ...
Integenx... Integra Group Diagnostics... Integral Molecular .....
Integrated BioTherapeutics
.... Integrated
Diagnostics .... Integrated
Diagnostics InDi .... Integrated DNA Technologies ..... Integrated
Fuel...
... Integration Associates... Intelect
Medical
Intelleflex ... Intellia Therapeutics .....
Intellicyt
Automation Bio-systems ...
Intelligent Devices .... Intelligent Epitaxy Technology .....
Intellimedix ..... Intelliphage.... Intellirad
Control...
.Intellisense .... Intelomed ....Inter-4... Interactive Supercomputing
... Interdigital
Interlace ....
Intermagnetics General ...Intermolecular ... Intermune....
International Stem Cell ... Interpace
Biosciences ..... Interrad Medical ..... IntersectENT ....
Intersense... Intersystems ...
Intervalve.... InterVene .... Intevac.... Intra-Cellular Therapies
.....
Intralase ...... Intralytix .... Intrepida Bio .... Intrexon .....
Intrinsic Therapeutics
.... Intrinsity....
Introgen....
... Intuitive Biosciences .... Intuitive Genomics ..... Intuitive
Surgical.... Invenra ....
Invensense .... Inventev ..... Inverness
Innovations.... Invirsa ..... Invertix.... Invictus.... Inview
Technology....
Inviragen.... Invisage Technologies ....
....InvisionHeart .... Invision Medical ....
Invitae....
Invitrogen.... ...Invivosciences.... Invivo Therapeutics=
Holdings .... Invuity....
Inx Medical.... IoGyn .... Iomai.... ... Iomed....
IOmet
Pharma ..... Ion America Optics..... Ionic Materials ..... IonQ ....
Ion
Torrent.... Iovance Biotherapeutics ..... Iovation.... Iowa Thin
Film....
Ipierian.... IPG Photonics.... ... Iquum
...Irhythm...
iRobot... Iroko...Ironbridge.... ... Ironwood....
... .... Irvine Sensors... .... biopolymer
. .... Ischemia Care.... iSee ..... iSIGHT
Partners
.....
Isis.... Island Ddata....
Isogenis.... Isomark.... IsoPlexis .... Isoray....
Isothermal....
Isthmus Biosciences ..... IstoTechnologies....
itaconix....
I-Therapeutix..... Itherxm Pharmaceuticals.... Itraumacare... .. Itseez
..... Itzbig ..... Iveric bio .... Iwalk
LAAMScience
... LaBelle
Associates .....
LabNow
...Laborie Medical Technologies ... Labrys Biologics ... Lacerta
Therapeutics ..... Lactic
Solutions ..... Laguna
Pharmaceuticals (formerly ChanRx) ..... La Jolla
Pharmaceutical
... Lake Shore Cryotronics .... Landec
.... Landos Biopharma .... Lantern
Pharma ..... Lantheus
...
Lantos
Technologies ... Lariat Biosciences .... Laser
Design .... Lasergen ..... LaserMax ..... LaserMotive
... Laser Tissue
Welding .... Lattice Biologics ..... Lattice
Biotech .... LaunchPad Medical .... Lawrie ... Lazarus Effect
..... LDR
Holding
..... Leading Edge Crystal Technologies ..... Lead Therapeutics
... LeafBio .... LeCroy ... LED Lighting
Fixtures
... Lehigh
Technologies .... Leica Microsystems
.....
LetoSolutions .... Lexicon
Genetics
... LexaGene ..... Lexicon Pharmaceuticals ... Leuko .... Leyden Energy
...
Libra
BioSciences .... LifeCell ... LifeGen
Technologies ...
Life Image ... LifeMine Therapeutics .... LifeSprout ....
Life Technologies
....
Ligand
Pharmaceuticals ....Ligon Discovery ... Lightpointe
... Light Sciences Oncology ... LightWorks Optics
....
Lilliputian Systems
.... Lily Robotics ..... Linares Management
Associates
.. Lingotek
... Linnaeus Therapeutics .... LinQuest .... Lionano .... Lion
Biotechnologies ..... Lipocine ....
LipoScience
...
Liquid Biotech ..... Liquidia
Technologies ...
Liquid Light ...
Liquid Metal
Battery ...
LiquidPiston ... Liquid Robotics ... Liquid X Printed Metals
....
LiQuifix ...
Lithium Technology
... LiveData ... . LiveLeaf
Bioscience .... LKC Technologies ... Locana.... Locus Biosciences ....
Lodo
Therapeutics .... Logical
Therapeutics
... LogicBio Therapeutics ..... Logos
Tech
... Lohocla Research
.....
Lombard Medical ..... Longeveron ..... Longeviti .... LonoCloud .....
Lookingglass ..... Loon Medical
..... Lotus Tissue
Repair
...
Loxo Oncology ... LPath Thera .... Lq3 Pharmaceuticals ....
LS9
...
Luca
Technologies .... Lucerno Dynamics .... Lucidux ...
Lucigen
.... LumaSense Technologies .... Lumena
Pharmaceuticals .... Lumen Bioscience .... Lumencor
... Lumense .... Lumera ... Lumicell Diagnostics
... Luminar Technologies ..... Luminary Micro ...
Luminex .... Luminus Devices ... Lumisyn
..... Lumitex
... LumiThera .... Lumos Pharma .... Luna Innovations
... Luna Technologies
... Lung Therapeutics .... Lutonix
... Luxtera
... Lycera ... LyGenesis ..... Lyncean ..... Lyndra
Therapeutic ... Lynntech ... Lynx Biosciences ... Lyra Therapeutics
..... Lysosomal Therapeutics ....
Lytro Therapeutics
uBiome .... UCAN
... UES
... Ulthera .... UltraCell ... Ultragenyx
....
Ultralife Batteries
...
Ultramet... Ultradian
Diagnostics ..... Ultraviolet Sciences ... Unbounded Robotics
.... Unchained Labs .... UNIAX
... Unica
... Unidym ... UniEnergy Technologies ..... Unified
Nexsys
.... Unilife ..... Uni-Pixel .... Uniqure
.... United
Devices ... United
Therapeutics
... United Therapies ..... Unity Biotechnology .... Universal
Cells ...... Universal
Display ... Universal
Robots ..... Universal
Technical Resources .... Universal
Technology .... Unleash Immuno
Oncolytics ..... Unum Therapeutics .... Unwired
Nation ... Uptake Medical
... UQM Technologies ... Urbix Resources ....
Urigen
Pharmaceuticals
.... UroGene Pharma ..... US
Nanocorp ... Uroplasty ..... US Bioscience ..... US
Silicones ... UTC Power .... Utilidata ... Utron
.....
UVision360
X4 Pharmaceuticals .....
Xanofi ... Xanthus
Pharmaceuticals
... XBiotech USA ..... X-Biotix Therapeutics .... X-Body
Biosciences
... Xcede Technologies ..... XCELL BIOLOGIX .....
Xcell Biosciences
....
Xcellerex ... XChanger
Companies .... Xencor .... X-energy ..... Xenetic Biosciences ....
Xenex
Disinfection Services .... Xenex
Healthcare Services ... XenoGen Biosystems .... Xenomics
... Xenoport ... Xeris
Pharmaceuticals ... Xetrios Therapeutics .... XF
Technologies .... xG Technology .... Xidex ... Xilio Therapeutics
(formerly Akrevia Thera) .... Xitronix
... XL
Hybrids ... Xlumena .... Xoc Pharmaceuticals ..... Xollai ...
Xolve
(formerly
Graphene Solutions)
... Xoma
... XProSciences (now Icagen) ..... X-Ray Optical .... X-Spine
.... XSunX
...
Xtalic .. Xtant Medical
Holdings ..... Xtent ...Xtreme Power
... XTuit Pharmaceuticals ....
Xunlight .... XyloCor Therapeutics .... Xynomic
Pharma